Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.
A benign neoplasm derived from glandular epithelium, in which cystic accumulations of retained secretions are formed. In some instances, considerable portions of the neoplasm, or even the entire mass, may be cystic. (Stedman, 25th ed)
A smooth, solid or cystic fibroepithelial (FIBROEPITHELIAL NEOPLASMS) tumor, usually found in the OVARIES but can also be found in the adnexal region and the KIDNEYS. It consists of a fibrous stroma with nests of epithelial cells that sometimes resemble the transitional cells lining the urinary bladder. Brenner tumors generally are benign and asymptomatic. Malignant Brenner tumors have been reported.
A neoplasm composed entirely of GRANULOSA CELLS, occurring mostly in the OVARY. In the adult form, it may contain some THECA CELLS. This tumor often produces ESTRADIOL and INHIBIN. The excess estrogen exposure can lead to other malignancies in women and PRECOCIOUS PUBERTY in girls. In rare cases, granulosa cell tumors have been identified in the TESTES.
A sex cord-gonadal stromal tumor consists of LEYDIG CELLS; SERTOLI CELLS; and FIBROBLASTS in varying proportions and degree of differentiation. Most such tumors produce ANDROGENS in the Leydig cells, formerly known as androblastoma or arrhenoblastoma. Androblastomas occur in the TESTIS or the OVARY causing precocious masculinization in the males, and defeminization, or virilization (VIRILISM) in the females. In some cases, the Sertoli cells produce ESTROGENS.
A gonadal stromal neoplasm composed only of THECA CELLS, occurring mostly in the postmenopausal OVARY. It is filled with lipid-containing spindle cells and produces ESTROGENS that can lead to ENDOMETRIAL HYPERPLASIA; UTERINE HEMORRHAGE; or other malignancies in postmenopausal women and sexual precocity in girls. When tumors containing theca cells also contain FIBROBLASTS, they are identified as thecoma-fibroma tumors with less active hormone production.
A malignant neoplasm derived from glandular epithelium, in which cystic accumulations of retained secretions are formed. The neoplastic cells manifest varying degrees of anaplasia and invasiveness, and local extension and metastases occur. Cystadenocarcinomas develop frequently in the ovaries, where pseudomucinous and serous types are recognized. (Stedman, 25th ed)
A malignant ovarian neoplasm, thought to be derived from primordial germ cells of the sexually undifferentiated embryonic gonad. It is the counterpart of the classical seminoma of the testis, to which it is both grossly and histologically identical. Dysgerminomas comprise 16% of all germ cell tumors but are rare before the age of 10, although nearly 50% occur before the age of 20. They are generally considered of low-grade malignancy but may spread if the tumor extends through its capsule and involves lymph nodes or blood vessels. (Dorland, 27th ed; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1646)
Gonadal neoplasm composed entirely of SERTOLI CELLS or may have a component of GRANULOSA CELLS. Some of the Sertoli cell tumors produce ESTROGEN or ANDROGENS, but seldom in sufficient quantity to cause clinical symptoms such as FEMINIZATION or masculinization (VIRILISM).
General term for CYSTS and cystic diseases of the OVARY.
A tumor consisting of displaced ectodermal structures along the lines of embryonic fusion, the wall being formed of epithelium-lined connective tissue, including skin appendages, and containing keratin, sebum, and hair. (Stedman, 25th ed)
Pathological processes of the OVARY.
Neoplasms derived from the primitive sex cord or gonadal stromal cells of the embryonic GONADS. They are classified by their presumed histogenesis and differentiation. From the sex cord, there are SERTOLI CELL TUMOR and GRANULOSA CELL TUMOR; from the gonadal stroma, LEYDIG CELL TUMOR and THECOMA. These tumors may be identified in either the OVARY or the TESTIS.
A cystic tumor of the ovary, containing thin, clear, yellow serous fluid and varying amounts of solid tissue, with a malignant potential several times greater than that of mucinous cystadenoma (CYSTADENOMA, MUCINOUS). It can be unilocular, parvilocular, or multilocular. It is often bilateral and papillary. The cysts may vary greatly in size. (Dorland, 27th ed; from Hughes, Obstetric-Gynecologic Terminology, 1972)
A true neoplasm composed of a number of different types of tissue, none of which is native to the area in which it occurs. It is composed of tissues that are derived from three germinal layers, the endoderm, mesoderm, and ectoderm. They are classified histologically as mature (benign) or immature (malignant). (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1642)
A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm but is often wrongly used as a synonym for "cancer." (From Dorland, 27th ed)
Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.
Histochemical localization of immunoreactive substances using labeled antibodies as reagents.
A malignant epithelial tumor with a glandular organization.
Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
Neoplasms containing cyst-like formations or producing mucin or serum.
Tumors or cancer of the SKIN.
Two or more abnormal growths of tissue occurring simultaneously and presumed to be of separate origin. The neoplasms may be histologically the same or different, and may be found in the same or different sites.
Tumors or cancers of the KIDNEY.
Abnormal growths of tissue that follow a previous neoplasm but are not metastases of the latter. The second neoplasm may have the same or different histological type and can occur in the same or different organs as the previous neoplasm but in all cases arises from an independent oncogenic event. The development of the second neoplasm may or may not be related to the treatment for the previous neoplasm since genetic risk or predisposing factors may actually be the cause.
An adenocarcinoma producing mucin in significant amounts. (From Dorland, 27th ed)
Tumors or cancer of the THYROID GLAND.
Conditions which cause proliferation of hemopoietically active tissue or of tissue which has embryonic hemopoietic potential. They all involve dysregulation of multipotent MYELOID PROGENITOR CELLS, most often caused by a mutation in the JAK2 PROTEIN TYROSINE KINASE.
DNA present in neoplastic tissue.
Tumors or cancer of the LUNG.
Tumors or cancer of the PAROTID GLAND.
Neoplasms developing from some structure of the connective and subcutaneous tissue. The concept does not refer to neoplasms located in connective or soft tissue.
Neoplasms associated with a proliferation of a single clone of PLASMA CELLS and characterized by the secretion of PARAPROTEINS.
Tumors or cancer of the APPENDIX.
Tumors or cancer of the LIVER.
A multilocular tumor with mucin secreting epithelium. They are most often found in the ovary, but are also found in the pancreas, appendix, and rarely, retroperitoneal and in the urinary bladder. They are considered to have low-grade malignant potential.
Tumors or cancer of the ENDOCRINE GLANDS.
Tumors or cancer of the GASTROINTESTINAL TRACT, from the MOUTH to the ANAL CANAL.
Carcinoma that arises from the PANCREATIC DUCTS. It accounts for the majority of cancers derived from the PANCREAS.
Experimentally induced new abnormal growth of TISSUES in animals to provide models for studying human neoplasms.
Neoplasms composed of vascular tissue. This concept does not refer to neoplasms located in blood vessels.
Tumors or cancer of the EYE.
Tumors or cancer of the NOSE.
Tumors or cancer of the SALIVARY GLANDS.
Tumors, cancer or other neoplasms produced by exposure to ionizing or non-ionizing radiation.
An adenocarcinoma containing finger-like processes of vascular connective tissue covered by neoplastic epithelium, projecting into cysts or the cavity of glands or follicles. It occurs most frequently in the ovary and thyroid gland. (Stedman, 25th ed)
A malignant neoplasm characterized by the formation of numerous, irregular, finger-like projections of fibrous stroma that is covered with a surface layer of neoplastic epithelial cells. (Stedman, 25th ed)
Tumors or cancer of the TESTIS. Germ cell tumors (GERMINOMA) of the testis constitute 95% of all testicular neoplasms.
Neoplasms composed of muscle tissue: skeletal, cardiac, or smooth. The concept does not refer to neoplasms located in muscles.
Neoplasms composed of glandular tissue, an aggregation of epithelial cells that elaborate secretions, and of any type of epithelium itself. The concept does not refer to neoplasms located in the various glands or in epithelial tissue.
A malignant cystic or semisolid tumor most often occurring in the ovary. Rarely, one is solid. This tumor may develop from a mucinous cystadenoma, or it may be malignant at the onset. The cysts are lined with tall columnar epithelial cells; in others, the epithelium consists of many layers of cells that have lost normal structure entirely. In the more undifferentiated tumors, one may see sheets and nests of tumor cells that have very little resemblance to the parent structure. (Hughes, Obstetric-Gynecologic Terminology, 1972, p184)
A benign epithelial tumor with a glandular organization.
Neoplasms of whatever cell type or origin, occurring in the extraskeletal connective tissue framework of the body including the organs of locomotion and their various component structures, such as nerves, blood vessels, lymphatics, etc.
Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES.
Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm.
Tumors or cancer of the UTERUS.
Tumors or cancer of the INTESTINES.
Neoplasms composed of sebaceous or sweat gland tissue or tissue of other skin appendages. The concept does not refer to neoplasms located in the sebaceous or sweat glands or in the other skin appendages.
Neoplasms located in the vasculature system, such as ARTERIES and VEINS. They are differentiated from neoplasms of vascular tissue (NEOPLASMS, VASCULAR TISSUE), such as ANGIOFIBROMA or HEMANGIOMA.
Sweat gland neoplasms are abnormal growths that can be benign or malignant, originating from the sweat glands (eccrine or apocrine) and found anywhere on the skin surface.
A general term for various neoplastic diseases of the lymphoid tissue.
Tumors or cancer located in bone tissue or specific BONES.
Tumors or cancer of the PALATE, including those of the hard palate, soft palate and UVULA.
Neoplasms composed of more than one type of neoplastic tissue.
Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin.
Tumors or cancer of the MANDIBLE.
Tumors or cancer of the BILE DUCTS.
Ability of neoplasms to infiltrate and actively destroy surrounding tissue.
Tumors or cancer of the THYMUS GLAND.
Tumors or cancer of the SPLEEN.
Tumors in any part of the heart. They include primary cardiac tumors and metastatic tumors to the heart. Their interference with normal cardiac functions can cause a wide variety of symptoms including HEART FAILURE; CARDIAC ARRHYTHMIAS; or EMBOLISM.

An improved method for the structural profiling of keratan sulfates: analysis of keratan sulfates from brain and ovarian tumors. (1/9962)

A previously developed method for the structural fingerprinting of keratan sulfates (Brown et al., Glycobiology, 5, 311-317, 1995) has been adapted for use with oligosaccharides fluorescently labeled with 2-aminobenzoic acid following keratanase II digestion. The oligosaccharides are separated by high-pH anion-exchange chromatography on a Dionex AS4A-SC column. This methodology permits quantitative analysis of labeled oligosaccharides which can be detected at the sub-nanogram ( approximately 100 fmol) level. Satisfactory calibration of this method can be achieved using commercial keratan sulfate standards. Keratan sulfates from porcine brain phosphocan and human ovarian tumors have been examined using this methodology, and their structural features are discussed.  (+info)

Role of dexamethasone dosage in combination with 5-HT3 antagonists for prophylaxis of acute chemotherapy-induced nausea and vomiting. (2/9962)

Dexamethasone (20 mg) or its equivalent in combination with 5-HT3 antagonists appears to be the gold-standard dose for antiemetic prophylaxis. Additional to concerns about the use of corticosteroids with respect to enhanced tumour growth or impaired killing of the tumour cells, there is evidence that high-dosage dexamethasone impairs the control of delayed nausea and emesis, whereas lower doses appear more beneficial. To come closer to the most adequate dose, we started a prospective, single-blind, randomized trial investigating additional dosage of 8 or 20 mg dexamethasone to tropisetron (Navoban), a 5-HT3 receptor antagonist, in cis-platinum-containing chemotherapy. After an interim analysis of 121 courses of chemotherapy in 69 patients, we have been unable to detect major differences between both treatment alternatives. High-dose dexamethasone (20 mg) had no advantage over medium-dose dexamethasone with respect to objective and subjective parameters of acute and delayed nausea and vomiting. In relation to concerns about the use of corticosteroids in non-haematological cancer chemotherapy, we suggest that 8 mg or its equivalent should be used in combination with 5-HT3 antagonists until further research proves otherwise.  (+info)

Cancer risk in close relatives of women with early-onset breast cancer--a population-based incidence study. (3/9962)

Inherited susceptibility to breast cancer is associated with an early onset and bilateral disease. The extent of familial risks has not, however, been fully assessed in population-based incidence studies. The purpose of the study was to quantify the risks for cancers of the breast, ovary and other sites of close relatives of women in whom breast cancer was diagnosed at an early age. Records collected between 1943 and 1990 at the Danish Cancer Registry were searched, and 2860 women were found in whom breast cancer was diagnosed before age 40. Population registers and parish records were used to identify 14 973 parents, siblings and offspring of these women. Cancer occurrence through to 31 December 1993 was determined within the Cancer Registry's files and compared with national incidence rates. Women with early-onset breast cancer were at a nearly fourfold increased risk of developing a new cancer later in life (268 observed vs. 68.9 expected). The excess risk was most evident for second cancer of the breast (181 vs. 24.5) and for ovarian cancer (20 vs. 3.3). For mothers and sisters, risks for cancers of the breast and ovary were significantly increased by two- to threefold. Bilateral breast cancer and breast-ovarian cancer were very strong predictors of familial risks, with one in four female relatives predicted to develop breast and/or ovarian cancer by age 75. Mothers had a slightly increased risk of colon cancer, but not endometrial cancer. The risk for breast cancer was also increased among fathers (standardized incidence ratio 2.5; 95% CI 0.5-7.4) and especially brothers (29; 7.7-74), although based on small numbers. The risk for prostatic cancer was unremarkable. In this large population-based survey, the first-degree relatives of women who developed breast cancer before age 40 were prone to ovarian cancer as well as male and female breast cancer, but not other tumours that may share susceptibility genes with breast cancer.  (+info)

Frequent silencing of the GPC3 gene in ovarian cancer cell lines. (4/9962)

GPC3 encodes a glypican integral membrane protein and is mutated in the Simpson-Golabi-Behmel syndrome. Simpson-Golabi-Behmel syndrome, an X-linked condition, is characterized by pre- and postnatal overgrowth as well as by various other abnormalities, including increased risk of embryonal tumors. The GPC3 gene is located at Xq26, a region frequently deleted in advanced ovarian cancers. To determine whether GPC3 is a tumor suppressor in ovarian neoplasia, we studied its expression and mutational status in 13 ovarian cancer cell lines. No mutations were found in GPC3, but its expression was lost in four (31%) of the cell lines analyzed. In an of the cases where GPC3 expression was lost, the GPC3 promoter was hypermethylated, as demonstrated by Southern analysis. Expression of GPC3 was restored by treatment of the cells with the demethylating agent 5-aza-2'-deoxycytidine. A colony-forming assay confirmed that ectopic GPC3 expression inhibited the growth of ovarian cancer cell lines. Our results show that GPC3, a gene involved in the control of organ growth, is frequently inactivated in a subset of ovarian cancers and suggest that it may function as a tumor suppressor in the ovary.  (+info)

Survival in familial, BRCA1-associated, and BRCA2-associated epithelial ovarian cancer. United Kingdom Coordinating Committee for Cancer Research (UKCCCR) Familial Ovarian Cancer Study Group. (5/9962)

The natural history of hereditary and BRCA1- and BRCA2-associated epithelial ovarian cancer may differ from that of sporadic disease. The purpose of this study was to compare the clinical characteristics of BRCA1- and BRCA2-associated hereditary ovarian cancer, hereditary ovarian cancer with no identified BRCA1/2 mutation, and ovarian cancer in population-based controls. BRCA1 and BRCA2 mutation testing was carried out on index cases from 119 families with site-specific epithelial ovarian cancer or breast-ovarian cancer. We estimated overall survival in 151 patients from 57 BRCA1 and BRCA2 mutation families and compared it with that in 119 patients from 62 families in which a BRCA1/2 mutation was not identified. We compared clinical outcome and data on tumor histopathology, grade, and stage. We also compared survival in familial epithelial ovarian cancer, whether or not a mutation was identified, with that of an age-matched set of population control cases. Overall survival at 5 years was 21% (95% confidence interval, 14-28) in cases from BRCA1 mutation families, 25% (8-42) in BRCA2 mutation families, and 19% (12-26) in families with no identified mutation (P = 0.91). Survival in familial ovarian cancer cases as a whole was significantly worse than for population controls (P = 0.005). In the familial cases, we found no differences in histopathological type, grade, or stage according to mutation status. Compared to population control cases, mucinous tumors occurred less frequently in the familial cases (2 versus 12%, P<0.001), and a greater proportion of the familial cases presented with advanced disease (83% stage III/IV versus 56%; P = 0.001). We have shown that survival in familial ovarian cancer cases is worse than that in sporadic cases, whether or not a BRCA1/2 mutation was identified, perhaps reflecting a difference in biology analogous to that observed in breast cancer.  (+info)

Survival after breast cancer in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers. (6/9962)

BACKGROUND: Studies of survival following breast and ovarian cancers in BRCA1 and/or BRCA2 mutation carriers have yielded conflicting results. We undertook an analysis of a community-based study of Ashkenazi Jews to investigate the effect of three founder mutations in BRCA1 and BRCA2 on survival among patients with breast or ovarian cancer. METHODS: We collected blood samples and questionnaire data from 5318 Ashkenazi Jewish volunteers. The blood samples were tested for 185delAG (two nucleotide deletion) and 5382insC (single nucleotide insertion) mutations in BRCA1 and the 6174delT (single nucleotide deletion) mutation in BRCA2. To estimate survival differences in the affected relatives according to their BRCA1 and/or BRCA2 mutation carrier status, we devised and applied a novel extension of the kin-cohort method. RESULTS: Fifty mutation carriers reported that 58 of their first-degree relatives had been diagnosed with breast cancer and 10 with ovarian cancer; 907 noncarriers reported 979 first-degree relatives with breast cancer and 116 with ovarian cancer. Kaplan-Meier estimates of median survival after breast cancer were 16 years (95% confidence interval [CI] = 11-40) in the relatives of carriers and 18 years (95% CI = 15-22) in the relatives of noncarriers, a difference that was not statistically significant (two-sided P = .87). There was also no difference in survival times among the 126 first-degree relatives with ovarian cancer. We found no survival difference between patients with breast or ovarian cancer who were inferred carriers of BRCA1 and/or BRCA2 mutations and noncarriers. CONCLUSIONS: Carriers of BRCA1 and BRCA2 mutations appeared to have neither better nor worse survival prognosis.  (+info)

In vivo localization of [(111)In]-DTPA-D-Phe1-octreotide to human ovarian tumor xenografts induced to express the somatostatin receptor subtype 2 using an adenoviral vector. (7/9962)

Adenoviral vectors, encoding genes for cell surface antigens or receptors, have been used to induce their high level expression on tumor cells in vitro and in vivo. These induced antigens and receptors can then be targeted with radiolabeled antibodies or peptides for potential radiotherapeutic applications. The purpose of this study was to determine a dosing schema of an adenoviral vector encoding the human somatostatin receptor subtype 2 (AdCMVhSSTr2) for achieving the highest tumor localization of [(111)In]-DTPA-D-Phe1-octreotide, which binds to this receptor, in a human ovarian cancer model as a prelude to future therapy studies. AdCMVhSSTr2 was produced and used to induce hSSTr2 on A427 human nonsmall cell lung cancer cells and on SKOV3.ipl human ovarian cancer cells in vitro, as demonstrated by competitive binding assays using [125I]-Tyr1-somatostatin and [(111)In]-DTPA-D-Phe1-octreotide. Mice bearing i.p. SKOV3.ip1 tumors administered 1 x 10(9) plaque-forming units of AdCMVhSSTr2 i.p. 5 days after tumor cell inoculation, followed by an i.p. injection of [(111)In]-DTPA-D-Phe1-octreotide 2 days later, showed a range of 15.3-60.4% median injected dose/gram (ID/g) in tumor at 4 h after injection compared with 3.5% ID/g when [125I]-Tyr1-somatostatin was administered and 0.3% ID/g when the negative control peptide [125I]-mIP-bombesin was administered. Mice administered a control adenoviral vector encoding the gastrin-releasing peptide receptor did not have tumor localization of [(111)In]-DTPA-D-Phe1-octreotide (<1.6% ID/g), demonstrating specificity of [(111)In]-DTPA-D-Phe1-octreotide for the AdCMVhSSTr2 induced tumor cells. In another set of experiments, the tumor localization of [(111)In]-DTPA-D-Phe1-octreotide was not different 1, 2, or 4 days after AdCMVhSSTr2 injection (31.8, 37.7, and 40.7% ID/g, respectively; P = 0.88), indicating that multiple injections of radiolabeled peptide can be administered with equivalent uptake over a 4-day period. [(111)In]-DTPA-D-Phe1-octreotide tumor localization in animals administered AdCMVhSSTr2 on consecutive days or 2 days apart was 22.4% ID/g and 53.2% ID/g, respectively (P = 0.009) when [(111)In]-DTPA-D-Phe1-octreotide was given 1 day after the second AdCMVhSSTr2 injection. There was no difference in [(111)In]-DTPA-D-Phe1-octreotide localization after a single AdCMVhSSTr2 injection (40.7% ID/g) or two injections of AdCMVhSSTr2 given 1 (45.9% ID/g) or 2 (53.2% ID/g) days apart, where [(111)In]-DTPA-D-Phe1-octreotide was given in each case 4 days after the first AdCMVhSSTr2 injection (P = 0.65). Therefore, two AdCMVhSSTr2 injections did not increase [(111)In]-DTPA-D-Phe1-octreotide tumor localization compared with one injection, which eliminates concerns about an immune response to a second dose of AdCMVhSSTr2. This will be the basis for a therapeutic protocol with multiple administrations of an octreotide analogue labeled with a therapeutic radioisotope.  (+info)

Combination of theanine with doxorubicin inhibits hepatic metastasis of M5076 ovarian sarcoma. (8/9962)

Theanine is a peculiar amino acid existing in green tea leaves, which was previously indicated to enhance the antitumor activity of doxorubicin. In the present study, the effect of combination of theanine with doxorubicin against hepatic metastasis of M5076 ovarian sarcoma was investigated. The primary tumor was significantly reduced by the combined treatment on M5076 transplanted (s.c.) mice. The liver weight of control mice increased to twice the normal level because of hepatic metastasis of M5076. In contrast, the injection of doxorubicin alone or theanine plus doxorubicin suppressed the increase in liver weight and inhibited hepatic metastasis. Moreover, the liver weights and metastasis scores demonstrated that theanine enhanced the inhibition of hepatic metastasis induced by doxorubicin. Furthermore, in vitro experiments indicated that theanine increased the intracellular concentration of doxorubicin remaining in M5076 cells. This action suggests that theanine leads the enhancement of the suppressive efficacy of doxorubicin on hepatic metastasis in vivo. Therefore, it was proved that theanine increased not only the antitumor activity on primary tumor but also the metastasis-suppressive efficacy of doxorubicin. The effect of theanine on the efficacy of antitumor agents is expected to be applicable in clinical cancer chemotherapy.  (+info)

Ovarian neoplasms refer to abnormal growths or tumors in the ovary, which can be benign (non-cancerous) or malignant (cancerous). These growths can originate from various cell types within the ovary, including epithelial cells, germ cells, and stromal cells. Ovarian neoplasms are often classified based on their cell type of origin, histological features, and potential for invasive or metastatic behavior.

Epithelial ovarian neoplasms are the most common type and can be further categorized into several subtypes, such as serous, mucinous, endometrioid, clear cell, and Brenner tumors. Some of these epithelial tumors have a higher risk of becoming malignant and spreading to other parts of the body.

Germ cell ovarian neoplasms arise from the cells that give rise to eggs (oocytes) and can include teratomas, dysgerminomas, yolk sac tumors, and embryonal carcinomas. Stromal ovarian neoplasms develop from the connective tissue cells supporting the ovary and can include granulosa cell tumors, thecomas, and fibromas.

It is essential to diagnose and treat ovarian neoplasms promptly, as some malignant forms can be aggressive and potentially life-threatening if not managed appropriately. Regular gynecological exams, imaging studies, and tumor marker tests are often used for early detection and monitoring of ovarian neoplasms. Treatment options may include surgery, chemotherapy, or radiation therapy, depending on the type, stage, and patient's overall health condition.

Cystadenoma is a type of benign tumor (not cancerous), which arises from glandular epithelial cells and is covered by a thin layer of connective tissue. These tumors can develop in various locations within the body, including the ovaries, pancreas, and other organs that contain glands.

There are two main types of cystadenomas: serous and mucinous. Serous cystadenomas are filled with a clear or watery fluid, while mucinous cystadenomas contain a thick, gelatinous material. Although they are generally not harmful, these tumors can grow quite large and cause discomfort or other symptoms due to their size or location. In some cases, cystadenomas may undergo malignant transformation and develop into cancerous tumors, known as cystadenocarcinomas. Regular medical follow-up and monitoring are essential for individuals diagnosed with cystadenomas to ensure early detection and treatment of any potential complications.

A Brenner tumor is a rare type of benign (non-cancerous) ovarian tumor that originates from the tissue that lines the ovary (the epithelium). These tumors are typically small, slow-growing, and asymptomatic, although in some cases they may cause abdominal discomfort or bloating.

Brenner tumors are composed of transitional cells, which are similar to the cells found in the urinary bladder. They are usually solid and contain areas of calcification (calcium deposits). While most Brenner tumors are benign, a small percentage may become malignant (cancerous) and spread to other parts of the body.

The exact cause of Brenner tumors is not known, but they are more common in older women and are often found incidentally during routine pelvic exams or imaging studies. Treatment typically involves surgical removal of the tumor, and the prognosis is generally excellent, especially for benign tumors.

A Granulosa Cell Tumor is a type of sex cord-stromal tumor, which are uncommon neoplasms that arise from the supporting cells of the ovary or testis. These tumors account for approximately 5% of all ovarian tumors and can occur at any age, but they are most commonly found in perimenopausal and postmenopausal women.

Granulosa cell tumors originate from the granulosa cells, which are normally responsible for producing estrogen and supporting the development of the egg within the ovarian follicle. These tumors can be functional, meaning they produce hormones, or nonfunctional. Functional granulosa cell tumors often secrete estrogen, leading to symptoms such as irregular menstrual periods, postmenopausal bleeding, and, in rare cases, the development of male characteristics (virilization) due to androgen production.

Granulosa cell tumors are typically slow-growing and can vary in size. They are often diagnosed at an early stage because they cause symptoms related to hormonal imbalances or, less commonly, due to abdominal pain or distention caused by the growing mass. The diagnosis is usually confirmed through imaging studies (such as ultrasound, CT, or MRI) and a biopsy or surgical removal of the tumor, followed by histopathological examination.

Treatment for granulosa cell tumors typically involves surgery to remove the tumor and, in some cases, adjacent organs if there is evidence of spread. The role of chemotherapy and radiation therapy is less clear, but they may be used in certain situations, such as advanced-stage disease or high-risk features. Regular follow-up with imaging studies and tumor marker measurements (such as inhibin) is essential due to the risk of recurrence, even many years after initial treatment.

A Sertoli-Leydig cell tumor is a rare type of sex cord-stromal tumor that develops in the ovaries. These tumors arise from the cells that produce hormones and help to form and maintain the ovarian tissue. Sertoli-Leydig cell tumors can occur in people of any age but are most commonly found in women between the ages of 20 and 40.

These tumors can be functional, meaning they produce hormones, or nonfunctional. Functional Sertoli-Leydig cell tumors may cause symptoms related to the production of male hormones (androgens), such as excess facial hair, a deepened voice, and irregular menstrual periods. Nonfunctional tumors typically do not cause any specific symptoms and are often found during routine pelvic examinations or imaging studies performed for other reasons.

Sertoli-Leydig cell tumors are usually slow-growing and can vary in size. Most of these tumors are benign (not cancerous), but some can be malignant (cancerous) and may spread to other parts of the body. Treatment typically involves surgical removal of the tumor, and additional therapies such as chemotherapy or radiation therapy may be recommended depending on the stage and grade of the tumor. Regular follow-up care is essential to monitor for any recurrence of the tumor.

A thecoma is a type of ovarian sex cord-stromal tumor, which are rare tumors that develop from the supporting cells (stromal cells) or the cells that produce hormones (sex cord cells) in the ovary. These tumors account for about 2% of all ovarian tumors.

Thecomas specifically arise from stromal cells that produce estrogen and other sex hormones. They are typically slow-growing and may not cause any symptoms, or they may cause symptoms related to hormonal imbalances such as irregular menstrual periods, vaginal bleeding, or postmenopausal bleeding. In some cases, thecomas can also grow large enough to cause abdominal discomfort or bloating.

Most thecomas are benign (non-cancerous), but a small percentage of them can be malignant (cancerous) and may spread to other parts of the body. Treatment for thecomas typically involves surgical removal of the tumor, and in some cases, hormonal therapy or chemotherapy may also be recommended.

Cystadenocarcinoma is a type of tumor that arises from the epithelial lining of a cyst, and it has the potential to invade surrounding tissues and spread (metastasize) to other parts of the body. It typically affects glandular organs such as the ovaries, pancreas, and salivary glands.

Cystadenocarcinomas can be classified into two types: serous and mucinous. Serous cystadenocarcinomas produce a watery fluid, while mucinous cystadenocarcinomas produce a thick, mucus-like fluid. Both types of tumors can be benign or malignant, but malignant cystadenocarcinomas are more aggressive and have a higher risk of metastasis.

Symptoms of cystadenocarcinoma depend on the location and size of the tumor. In some cases, there may be no symptoms until the tumor has grown large enough to cause pain or other problems. Treatment typically involves surgical removal of the tumor, along with any affected surrounding tissue. Chemotherapy and radiation therapy may also be used in some cases to help prevent recurrence or spread of the cancer.

Dysgerminoma is a type of germ cell tumor that develops in the ovaries. It is a malignant (cancerous) tumor that primarily affects girls and women of reproductive age, although it can occur at any age. Dysgerminomas are composed of large, round, or polygonal cells with clear cytoplasm and distinct cell borders, arranged in nests or sheets. They may also contain lymphoid aggregates and may produce hormones such as estrogen or testosterone.

Dysgerminomas are usually unilateral (affecting one ovary), but they can be bilateral (affecting both ovaries) in about 10-15% of cases. They tend to grow and spread rapidly, so early detection and treatment are crucial for a favorable prognosis.

The standard treatment for dysgerminoma is surgical removal of the affected ovary or ovaries, followed by chemotherapy with agents such as bleomycin, etoposide, and cisplatin (BEP). With appropriate treatment, the five-year survival rate for patients with dysgerminoma is high, ranging from 80% to 95%.

A Sertoli cell tumor is a rare type of sex-cord stromal tumor that develops in the testicles or, more rarely, in the ovaries. These tumors arise from the Sertoli cells, which are specialized cells within the testicle that help to nurture and protect the developing sperm cells. In the ovary, Sertoli cell tumors are thought to arise from similar cells that are part of the supporting tissue in the ovary.

Sertoli cell tumors can occur in people of any age but are most commonly found in middle-aged adults. They are usually slow-growing and may not cause any symptoms, especially if they are small. However, larger tumors or those that have spread (metastasized) may cause various symptoms depending on their location and size.

Symptoms of a Sertoli cell tumor can include:

* A painless lump or swelling in the testicle or ovary
* Abdominal pain or discomfort
* Bloating or a feeling of fullness in the abdomen
* Changes in bowel habits or urinary frequency
* Pain during sexual intercourse (in women)
* Hormonal imbalances, such as gynecomastia (breast development) in men or menstrual irregularities in women.

Diagnosis of a Sertoli cell tumor typically involves a combination of imaging tests, such as ultrasound, CT scan, or MRI, and blood tests to check for elevated levels of certain hormones that may be produced by the tumor. A biopsy may also be performed to confirm the diagnosis and determine the tumor's grade and stage.

Treatment for Sertoli cell tumors typically involves surgical removal of the tumor, along with any affected lymph nodes or other tissues. Additional treatments, such as radiation therapy or chemotherapy, may be recommended in cases where the tumor has spread or is at a higher risk of recurrence. Regular follow-up care is also important to monitor for any signs of recurrence or new tumors.

An ovarian cyst is a sac or pouch filled with fluid that forms on the ovary. Ovarian cysts are quite common in women during their childbearing years, and they often cause no symptoms. In most cases, ovarian cysts disappear without treatment over a few months. However, larger or persistent cysts may require medical intervention, including surgical removal.

There are various types of ovarian cysts, such as functional cysts (follicular and corpus luteum cysts), which develop during the menstrual cycle due to hormonal changes, and non-functional cysts (dermoid cysts, endometriomas, and cystadenomas), which can form due to different causes.

While many ovarian cysts are benign, some may have malignant potential or indicate an underlying medical condition like polycystic ovary syndrome (PCOS). Regular gynecological check-ups, including pelvic examinations and ultrasounds, can help detect and monitor ovarian cysts.

A dermoid cyst is a type of benign (non-cancerous) growth that typically develops during embryonic development. It is a congenital condition, which means it is present at birth, although it may not become apparent until later in life. Dermoid cysts are most commonly found in the skin or the ovaries of women, but they can also occur in other areas of the body, such as the spine or the brain.

Dermoid cysts form when cells that are destined to develop into skin and its associated structures, such as hair follicles and sweat glands, become trapped during fetal development. These cells continue to grow and multiply, forming a sac-like structure that contains various types of tissue, including skin, fat, hair, and sometimes even teeth or bone.

Dermoid cysts are usually slow-growing and may not cause any symptoms unless they become infected or rupture. In some cases, they may cause pain or discomfort if they press on nearby structures. Treatment typically involves surgical removal of the cyst to prevent complications and alleviate symptoms.

Ovarian diseases refer to a range of conditions that affect the function and health of the ovaries, which are the female reproductive organs responsible for producing eggs (oocytes) and female hormones estrogen and progesterone. These diseases can be categorized into functional disorders, infectious and inflammatory diseases, neoplastic diseases, and other conditions that impact ovarian function. Here's a brief overview of some common ovarian diseases:

1. Functional Disorders: These are conditions where the ovaries experience hormonal imbalances or abnormal functioning, leading to issues such as:
* Polycystic Ovary Syndrome (PCOS): A condition characterized by hormonal imbalances that can cause irregular periods, cysts in the ovaries, and symptoms like acne, weight gain, and infertility.
* Functional Cysts: Fluid-filled sacs that develop within the ovary, usually as a result of normal ovulation (follicular or corpus luteum cysts). They're typically harmless and resolve on their own within a few weeks or months.
2. Infectious and Inflammatory Diseases: These conditions are caused by infections or inflammation affecting the ovaries, such as:
* Pelvic Inflammatory Disease (PID): An infection that spreads to the reproductive organs, including the ovaries, fallopian tubes, and uterus. It's often caused by sexually transmitted bacteria like Chlamydia trachomatis or Neisseria gonorrhoeae.
* Tuberculosis (TB): A bacterial infection that can spread to the ovaries and cause inflammation, abscesses, or scarring.
3. Neoplastic Diseases: These are conditions where abnormal growths or tumors develop in the ovaries, which can be benign (non-cancerous) or malignant (cancerous). Examples include:
* Ovarian Cysts: While some cysts are functional and harmless, others can be neoplastic. Benign tumors like fibromas, dermoids, or cystadenomas can grow significantly larger and cause symptoms like pain or bloating. Malignant tumors include epithelial ovarian cancer, germ cell tumors, and sex cord-stromal tumors.
4. Other Conditions: Various other conditions can affect the ovaries, such as:
* Polycystic Ovary Syndrome (PCOS): A hormonal disorder that causes enlarged ovaries with small cysts. It's associated with irregular periods, infertility, and increased risk of diabetes, high blood pressure, and heart disease.
* Premature Ovarian Failure (POF): Also known as primary ovarian insufficiency, it occurs when the ovaries stop functioning before age 40, leading to menstrual irregularities, infertility, and early onset of menopause.

It's essential to consult a healthcare professional if you experience any symptoms related to your reproductive system or suspect an issue with your ovaries. Early detection and treatment can significantly improve the prognosis for many conditions affecting the ovaries.

Sex cord-gonadal stromal tumors are a type of rare cancer that develops in the cells of the ovaries or testicles that produce hormones and help to form ova or sperm. These tumors can be benign (noncancerous) or malignant (cancerous), and they can occur in both males and females, although they are more common in females.

There are several subtypes of sex cord-gonadal stromal tumors, including granulosa cell tumors, thecomas, fibromas, Sertoli cell tumors, Leydig cell tumors, and gonadoblastomas. The symptoms and treatment options for these tumors depend on several factors, including the type and stage of the tumor, the patient's age and overall health, and whether the tumor is producing hormones.

Common symptoms of sex cord-gonadal stromal tumors may include abdominal pain or swelling, bloating, irregular menstrual periods, vaginal bleeding, or a feeling of fullness in the abdomen. In some cases, these tumors may produce hormones that can cause additional symptoms, such as breast tenderness, acne, or voice deepening.

Treatment for sex cord-gonadal stromal tumors typically involves surgery to remove the tumor and any affected tissue. Depending on the stage and type of the tumor, additional treatments such as chemotherapy or radiation therapy may also be recommended. Regular follow-up care is important to monitor for recurrence and manage any long-term effects of treatment.

A serous cystadenoma is a type of benign tumor that arises from the epithelial cells lining the serous glands, which are glands that produce a watery, lubricating fluid. This type of tumor typically develops in the ovary or the pancreas.

Serous cystadenomas of the ovary are usually filled with a clear, watery fluid and have multiple loculations (compartments). They can vary in size from a few millimeters to several centimeters in diameter. Although these tumors are benign, they can cause symptoms if they become large enough to press on surrounding organs or if they rupture and release their contents into the abdominal cavity.

Serous cystadenomas of the pancreas are less common than ovarian serous cystadenomas. They typically occur in the tail of the pancreas and can range in size from a few millimeters to several centimeters in diameter. These tumors are usually asymptomatic, but they can cause symptoms such as abdominal pain or discomfort if they become large enough to press on surrounding organs.

It is important to note that while serous cystadenomas are generally benign, there is a small risk that they may undergo malignant transformation and develop into a type of cancer known as a serous cystadenocarcinoma. For this reason, it is important for patients with these tumors to be followed closely by a healthcare provider and to have regular imaging studies and/or surgical excision to monitor for any changes in the tumor.

A teratoma is a type of germ cell tumor, which is a broad category of tumors that originate from the reproductive cells. A teratoma contains developed tissues from all three embryonic germ layers: ectoderm, mesoderm, and endoderm. This means that a teratoma can contain various types of tissue such as hair, teeth, bone, and even more complex organs like eyes, thyroid, or neural tissue.

Teratomas are usually benign (non-cancerous), but they can sometimes be malignant (cancerous) and can spread to other parts of the body. They can occur anywhere in the body, but they're most commonly found in the ovaries and testicles. When found in these areas, they are typically removed surgically.

Teratomas can also occur in other locations such as the sacrum, coccyx (tailbone), mediastinum (the area between the lungs), and pineal gland (a small gland in the brain). These types of teratomas can be more complex to treat due to their location and potential to cause damage to nearby structures.

Carcinoma is a type of cancer that develops from epithelial cells, which are the cells that line the inner and outer surfaces of the body. These cells cover organs, glands, and other structures within the body. Carcinomas can occur in various parts of the body, including the skin, lungs, breasts, prostate, colon, and pancreas. They are often characterized by the uncontrolled growth and division of abnormal cells that can invade surrounding tissues and spread to other parts of the body through a process called metastasis. Carcinomas can be further classified based on their appearance under a microscope, such as adenocarcinoma, squamous cell carcinoma, and basal cell carcinoma.

Neoplasm staging is a systematic process used in medicine to describe the extent of spread of a cancer, including the size and location of the original (primary) tumor and whether it has metastasized (spread) to other parts of the body. The most widely accepted system for this purpose is the TNM classification system developed by the American Joint Committee on Cancer (AJCC) and the Union for International Cancer Control (UICC).

In this system, T stands for tumor, and it describes the size and extent of the primary tumor. N stands for nodes, and it indicates whether the cancer has spread to nearby lymph nodes. M stands for metastasis, and it shows whether the cancer has spread to distant parts of the body.

Each letter is followed by a number that provides more details about the extent of the disease. For example, a T1N0M0 cancer means that the primary tumor is small and has not spread to nearby lymph nodes or distant sites. The higher the numbers, the more advanced the cancer.

Staging helps doctors determine the most appropriate treatment for each patient and estimate the patient's prognosis. It is an essential tool for communication among members of the healthcare team and for comparing outcomes of treatments in clinical trials.

Immunohistochemistry (IHC) is a technique used in pathology and laboratory medicine to identify specific proteins or antigens in tissue sections. It combines the principles of immunology and histology to detect the presence and location of these target molecules within cells and tissues. This technique utilizes antibodies that are specific to the protein or antigen of interest, which are then tagged with a detection system such as a chromogen or fluorophore. The stained tissue sections can be examined under a microscope, allowing for the visualization and analysis of the distribution and expression patterns of the target molecule in the context of the tissue architecture. Immunohistochemistry is widely used in diagnostic pathology to help identify various diseases, including cancer, infectious diseases, and immune-mediated disorders.

Adenocarcinoma is a type of cancer that arises from glandular epithelial cells. These cells line the inside of many internal organs, including the breasts, prostate, colon, and lungs. Adenocarcinomas can occur in any of these organs, as well as in other locations where glands are present.

The term "adenocarcinoma" is used to describe a cancer that has features of glandular tissue, such as mucus-secreting cells or cells that produce hormones. These cancers often form glandular structures within the tumor mass and may produce mucus or other substances.

Adenocarcinomas are typically slow-growing and tend to spread (metastasize) to other parts of the body through the lymphatic system or bloodstream. They can be treated with surgery, radiation therapy, chemotherapy, targeted therapy, or a combination of these treatments. The prognosis for adenocarcinoma depends on several factors, including the location and stage of the cancer, as well as the patient's overall health and age.

Pancreatic neoplasms refer to abnormal growths in the pancreas that can be benign or malignant. The pancreas is a gland located behind the stomach that produces hormones and digestive enzymes. Pancreatic neoplasms can interfere with the normal functioning of the pancreas, leading to various health complications.

Benign pancreatic neoplasms are non-cancerous growths that do not spread to other parts of the body. They are usually removed through surgery to prevent any potential complications, such as blocking the bile duct or causing pain.

Malignant pancreatic neoplasms, also known as pancreatic cancer, are cancerous growths that can invade and destroy surrounding tissues and organs. They can also spread (metastasize) to other parts of the body, such as the liver, lungs, or bones. Pancreatic cancer is often aggressive and difficult to treat, with a poor prognosis.

There are several types of pancreatic neoplasms, including adenocarcinomas, neuroendocrine tumors, solid pseudopapillary neoplasms, and cystic neoplasms. The specific type of neoplasm is determined through various diagnostic tests, such as imaging studies, biopsies, and blood tests. Treatment options depend on the type, stage, and location of the neoplasm, as well as the patient's overall health and preferences.

Neoplasms are abnormal growths of cells or tissues in the body that serve no physiological function. They can be benign (non-cancerous) or malignant (cancerous). Benign neoplasms are typically slow growing and do not spread to other parts of the body, while malignant neoplasms are aggressive, invasive, and can metastasize to distant sites.

Neoplasms occur when there is a dysregulation in the normal process of cell division and differentiation, leading to uncontrolled growth and accumulation of cells. This can result from genetic mutations or other factors such as viral infections, environmental exposures, or hormonal imbalances.

Neoplasms can develop in any organ or tissue of the body and can cause various symptoms depending on their size, location, and type. Treatment options for neoplasms include surgery, radiation therapy, chemotherapy, immunotherapy, and targeted therapy, among others.

Neoplasms: Neoplasms refer to abnormal growths of tissue that can be benign (non-cancerous) or malignant (cancerous). They occur when the normal control mechanisms that regulate cell growth and division are disrupted, leading to uncontrolled cell proliferation.

Cystic Neoplasms: Cystic neoplasms are tumors that contain fluid-filled sacs or cysts. These tumors can be benign or malignant and can occur in various organs of the body, including the pancreas, ovary, and liver.

Mucinous Neoplasms: Mucinous neoplasms are a type of cystic neoplasm that is characterized by the production of mucin, a gel-like substance produced by certain types of cells. These tumors can occur in various organs, including the ovary, pancreas, and colon. Mucinous neoplasms can be benign or malignant, and malignant forms are often aggressive and have a poor prognosis.

Serous Neoplasms: Serous neoplasms are another type of cystic neoplasm that is characterized by the production of serous fluid, which is a thin, watery fluid. These tumors commonly occur in the ovary and can be benign or malignant. Malignant serous neoplasms are often aggressive and have a poor prognosis.

In summary, neoplasms refer to abnormal tissue growths that can be benign or malignant. Cystic neoplasms contain fluid-filled sacs and can occur in various organs of the body. Mucinous neoplasms produce a gel-like substance called mucin and can also occur in various organs, while serous neoplasms produce thin, watery fluid and commonly occur in the ovary. Both mucinous and serous neoplasms can be benign or malignant, with malignant forms often being aggressive and having a poor prognosis.

Skin neoplasms refer to abnormal growths or tumors in the skin that can be benign (non-cancerous) or malignant (cancerous). They result from uncontrolled multiplication of skin cells, which can form various types of lesions. These growths may appear as lumps, bumps, sores, patches, or discolored areas on the skin.

Benign skin neoplasms include conditions such as moles, warts, and seborrheic keratoses, while malignant skin neoplasms are primarily classified into melanoma, squamous cell carcinoma, and basal cell carcinoma. These three types of cancerous skin growths are collectively known as non-melanoma skin cancers (NMSCs). Melanoma is the most aggressive and dangerous form of skin cancer, while NMSCs tend to be less invasive but more common.

It's essential to monitor any changes in existing skin lesions or the appearance of new growths and consult a healthcare professional for proper evaluation and treatment if needed.

Multiple primary neoplasms refer to the occurrence of more than one primary malignant tumor in an individual, where each tumor is unrelated to the other and originates from separate cells or organs. This differs from metastatic cancer, where a single malignancy spreads to multiple sites in the body. Multiple primary neoplasms can be synchronous (occurring at the same time) or metachronous (occurring at different times). The risk of developing multiple primary neoplasms increases with age and is associated with certain genetic predispositions, environmental factors, and lifestyle choices such as smoking and alcohol consumption.

Kidney neoplasms refer to abnormal growths or tumors in the kidney tissues that can be benign (non-cancerous) or malignant (cancerous). These growths can originate from various types of kidney cells, including the renal tubules, glomeruli, and the renal pelvis.

Malignant kidney neoplasms are also known as kidney cancers, with renal cell carcinoma being the most common type. Benign kidney neoplasms include renal adenomas, oncocytomas, and angiomyolipomas. While benign neoplasms are generally not life-threatening, they can still cause problems if they grow large enough to compromise kidney function or if they undergo malignant transformation.

Early detection and appropriate management of kidney neoplasms are crucial for improving patient outcomes and overall prognosis. Regular medical check-ups, imaging studies, and urinalysis can help in the early identification of these growths, allowing for timely intervention and treatment.

A "second primary neoplasm" is a distinct, new cancer or malignancy that develops in a person who has already had a previous cancer. It is not a recurrence or metastasis of the original tumor, but rather an independent cancer that arises in a different location or organ system. The development of second primary neoplasms can be influenced by various factors such as genetic predisposition, environmental exposures, and previous treatments like chemotherapy or radiation therapy.

It is important to note that the definition of "second primary neoplasm" may vary slightly depending on the specific source or context. In general medical usage, it refers to a new, separate cancer; however, in some research or clinical settings, there might be more precise criteria for defining and diagnosing second primary neoplasms.

Adenocarcinoma, mucinous is a type of cancer that begins in the glandular cells that line certain organs and produce mucin, a substance that lubricates and protects tissues. This type of cancer is characterized by the presence of abundant pools of mucin within the tumor. It typically develops in organs such as the colon, rectum, lungs, pancreas, and ovaries.

Mucinous adenocarcinomas tend to have a distinct appearance under the microscope, with large pools of mucin pushing aside the cancer cells. They may also have a different clinical behavior compared to other types of adenocarcinomas, such as being more aggressive or having a worse prognosis in some cases.

It is important to note that while a diagnosis of adenocarcinoma, mucinous can be serious, the prognosis and treatment options may vary depending on several factors, including the location of the cancer, the stage at which it was diagnosed, and the individual's overall health.

Thyroid neoplasms refer to abnormal growths or tumors in the thyroid gland, which can be benign (non-cancerous) or malignant (cancerous). These growths can vary in size and may cause a noticeable lump or nodule in the neck. Thyroid neoplasms can also affect the function of the thyroid gland, leading to hormonal imbalances and related symptoms. The exact causes of thyroid neoplasms are not fully understood, but risk factors include radiation exposure, family history, and certain genetic conditions. It is important to note that most thyroid nodules are benign, but a proper medical evaluation is necessary to determine the nature of the growth and develop an appropriate treatment plan.

Myeloproliferative disorders (MPDs) are a group of rare, chronic blood cancers that originate from the abnormal proliferation or growth of one or more types of blood-forming cells in the bone marrow. These disorders result in an overproduction of mature but dysfunctional blood cells, which can lead to serious complications such as blood clots, bleeding, and organ damage.

There are several subtypes of MPDs, including:

1. Chronic Myeloid Leukemia (CML): A disorder characterized by the overproduction of mature granulocytes (a type of white blood cell) in the bone marrow, leading to an increased number of these cells in the blood. CML is caused by a genetic mutation that results in the formation of the BCR-ABL fusion protein, which drives uncontrolled cell growth and division.
2. Polycythemia Vera (PV): A disorder characterized by the overproduction of all three types of blood cells - red blood cells, white blood cells, and platelets - in the bone marrow. This can lead to an increased risk of blood clots, bleeding, and enlargement of the spleen.
3. Essential Thrombocythemia (ET): A disorder characterized by the overproduction of platelets in the bone marrow, leading to an increased risk of blood clots and bleeding.
4. Primary Myelofibrosis (PMF): A disorder characterized by the replacement of normal bone marrow tissue with scar tissue, leading to impaired blood cell production and anemia, enlargement of the spleen, and increased risk of infections and bleeding.
5. Chronic Neutrophilic Leukemia (CNL): A rare disorder characterized by the overproduction of neutrophils (a type of white blood cell) in the bone marrow, leading to an increased number of these cells in the blood. CNL can lead to an increased risk of infections and organ damage.

MPDs are typically treated with a combination of therapies, including chemotherapy, targeted therapy, immunotherapy, and stem cell transplantation. The choice of treatment depends on several factors, including the subtype of MPD, the patient's age and overall health, and the presence of any comorbidities.

The term "DNA, neoplasm" is not a standard medical term or concept. DNA refers to deoxyribonucleic acid, which is the genetic material present in the cells of living organisms. A neoplasm, on the other hand, is a tumor or growth of abnormal tissue that can be benign (non-cancerous) or malignant (cancerous).

In some contexts, "DNA, neoplasm" may refer to genetic alterations found in cancer cells. These genetic changes can include mutations, amplifications, deletions, or rearrangements of DNA sequences that contribute to the development and progression of cancer. Identifying these genetic abnormalities can help doctors diagnose and treat certain types of cancer more effectively.

However, it's important to note that "DNA, neoplasm" is not a term that would typically be used in medical reports or research papers without further clarification. If you have any specific questions about DNA changes in cancer cells or neoplasms, I would recommend consulting with a healthcare professional or conducting further research on the topic.

Lung neoplasms refer to abnormal growths or tumors in the lung tissue. These tumors can be benign (non-cancerous) or malignant (cancerous). Malignant lung neoplasms are further classified into two main types: small cell lung carcinoma and non-small cell lung carcinoma. Lung neoplasms can cause symptoms such as cough, chest pain, shortness of breath, and weight loss. They are often caused by smoking or exposure to secondhand smoke, but can also occur due to genetic factors, radiation exposure, and other environmental carcinogens. Early detection and treatment of lung neoplasms is crucial for improving outcomes and survival rates.

Parotid neoplasms refer to abnormal growths or tumors in the parotid gland, which is the largest of the salivary glands and is located in front of the ear and extends down the neck. These neoplasms can be benign (non-cancerous) or malignant (cancerous).

Benign parotid neoplasms are typically slow-growing, painless masses that may cause facial asymmetry or difficulty in chewing or swallowing if they become large enough to compress surrounding structures. The most common type of benign parotid tumor is a pleomorphic adenoma.

Malignant parotid neoplasms, on the other hand, are more aggressive and can invade nearby tissues and spread to other parts of the body. They may present as rapidly growing masses that are firm or fixed to surrounding structures. Common types of malignant parotid tumors include mucoepidermoid carcinoma, adenoid cystic carcinoma, and squamous cell carcinoma.

The diagnosis of parotid neoplasms typically involves a thorough clinical evaluation, imaging studies such as CT or MRI scans, and fine-needle aspiration biopsy (FNAB) to determine the nature of the tumor. Treatment options depend on the type, size, and location of the neoplasm but may include surgical excision, radiation therapy, and chemotherapy.

Neoplasms of connective and soft tissue are abnormal growths or tumors that develop in the body's supportive tissues, such as cartilage, tendons, ligaments, fascia, and fat. These neoplasms can be benign (non-cancerous) or malignant (cancerous).

Benign connective and soft tissue neoplasms include:
- Lipomas: slow-growing, fatty tumors that develop under the skin.
- Fibromas: firm, benign tumors that develop in connective tissue such as tendons or ligaments.
- Nevi (plural of nevus): benign growths made up of cells called melanocytes, which produce pigment.

Malignant connective and soft tissue neoplasms include:
- Sarcomas: a type of cancer that develops in the body's supportive tissues such as muscle, bone, fat, cartilage, or blood vessels. There are many different types of sarcomas, including liposarcoma (fatty tissue), rhabdomyosarcoma (muscle), and osteosarcoma (bone).
- Desmoid tumors: a rare type of benign tumor that can become aggressive and invade surrounding tissues. While not considered cancerous, desmoid tumors can cause significant morbidity due to their tendency to grow and infiltrate nearby structures.

Connective and soft tissue neoplasms can present with various symptoms depending on their location and size. Treatment options include surgery, radiation therapy, chemotherapy, or a combination of these modalities. Regular follow-up care is essential to monitor for recurrence or metastasis (spread) of the tumor.

Plasma cell neoplasms are a type of cancer that originates from plasma cells, which are a type of white blood cell found in the bone marrow. These cells are responsible for producing antibodies to help fight off infections. When plasma cells become cancerous and multiply out of control, they can form a tumor called a plasmacytoma.

There are two main types of plasma cell neoplasms: solitary plasmacytoma and multiple myeloma. Solitary plasmacytoma is a localized tumor that typically forms in the bone, while multiple myeloma is a systemic disease that affects multiple bones and can cause a variety of symptoms such as bone pain, fatigue, and anemia.

Plasma cell neoplasms are diagnosed through a combination of tests, including blood tests, imaging studies, and bone marrow biopsy. Treatment options depend on the stage and extent of the disease, but may include radiation therapy, chemotherapy, and stem cell transplantation.

Appendiceal neoplasms refer to various types of tumors that can develop in the appendix, a small tube-like structure attached to the large intestine. These neoplasms can be benign or malignant and can include:

1. Adenomas: These are benign tumors that arise from the glandular cells lining the appendix. They are usually slow-growing and may not cause any symptoms.
2. Carcinoids: These are neuroendocrine tumors that arise from the hormone-producing cells in the appendix. They are typically small and slow-growing, but some can be aggressive and spread to other parts of the body.
3. Mucinous neoplasms: These are tumors that produce mucin, a slippery substance that can cause the appendix to become distended and filled with mucus. They can be low-grade (less aggressive) or high-grade (more aggressive) and may spread to other parts of the abdomen.
4. Adenocarcinomas: These are malignant tumors that arise from the glandular cells lining the appendix. They are relatively rare but can be aggressive and spread to other parts of the body.
5. Pseudomyxoma peritonei: This is a condition in which mucin produced by an appendiceal neoplasm leaks into the abdominal cavity, causing a jelly-like accumulation of fluid and tissue. It can be caused by both benign and malignant tumors.

Treatment for appendiceal neoplasms depends on the type and stage of the tumor, as well as the patient's overall health. Treatment options may include surgery, chemotherapy, or radiation therapy.

Liver neoplasms refer to abnormal growths in the liver that can be benign or malignant. Benign liver neoplasms are non-cancerous tumors that do not spread to other parts of the body, while malignant liver neoplasms are cancerous tumors that can invade and destroy surrounding tissue and spread to other organs.

Liver neoplasms can be primary, meaning they originate in the liver, or secondary, meaning they have metastasized (spread) to the liver from another part of the body. Primary liver neoplasms can be further classified into different types based on their cell of origin and behavior, including hepatocellular carcinoma, cholangiocarcinoma, and hepatic hemangioma.

The diagnosis of liver neoplasms typically involves a combination of imaging studies, such as ultrasound, CT scan, or MRI, and biopsy to confirm the type and stage of the tumor. Treatment options depend on the type and extent of the neoplasm and may include surgery, radiation therapy, chemotherapy, or liver transplantation.

Mucinous cystadenoma is a type of benign tumor that arises from the epithelial cells lining the mucous membranes of the body. It is most commonly found in the ovary, but can also occur in other locations such as the pancreas or appendix.

Mucinous cystadenomas are characterized by the production of large amounts of mucin, a slippery, gel-like substance that accumulates inside the tumor and causes it to grow into a cystic mass. These tumors can vary in size, ranging from a few centimeters to over 20 centimeters in diameter.

While mucinous cystadenomas are generally benign, they have the potential to become cancerous (mucinous cystadenocarcinoma) if left untreated. Symptoms of mucinous cystadenoma may include abdominal pain or swelling, bloating, and changes in bowel movements or urinary habits. Treatment typically involves surgical removal of the tumor.

Endocrine gland neoplasms refer to abnormal growths (tumors) that develop in the endocrine glands. These glands are responsible for producing hormones, which are chemical messengers that regulate various functions and processes in the body. Neoplasms can be benign or malignant (cancerous). Benign neoplasms tend to grow slowly and do not spread to other parts of the body. Malignant neoplasms, on the other hand, can invade nearby tissues and organs and may also metastasize (spread) to distant sites.

Endocrine gland neoplasms can occur in any of the endocrine glands, including:

1. Pituitary gland: located at the base of the brain, it produces several hormones that regulate growth and development, as well as other bodily functions.
2. Thyroid gland: located in the neck, it produces thyroid hormones that regulate metabolism and calcium balance.
3. Parathyroid glands: located near the thyroid gland, they produce parathyroid hormone that regulates calcium levels in the blood.
4. Adrenal glands: located on top of each kidney, they produce hormones such as adrenaline, cortisol, and aldosterone that regulate stress response, metabolism, and blood pressure.
5. Pancreas: located behind the stomach, it produces insulin and glucagon, which regulate blood sugar levels, and digestive enzymes that help break down food.
6. Pineal gland: located in the brain, it produces melatonin, a hormone that regulates sleep-wake cycles.
7. Gonads (ovaries and testicles): located in the pelvis (ovaries) and scrotum (testicles), they produce sex hormones such as estrogen, progesterone, and testosterone that regulate reproductive function and secondary sexual characteristics.

Endocrine gland neoplasms can cause various symptoms depending on the type and location of the tumor. For example, a pituitary gland neoplasm may cause headaches, vision problems, or hormonal imbalances, while an adrenal gland neoplasm may cause high blood pressure, weight gain, or mood changes.

Diagnosis of endocrine gland neoplasms typically involves a combination of medical history, physical examination, imaging studies such as CT or MRI scans, and laboratory tests to measure hormone levels. Treatment options may include surgery, radiation therapy, chemotherapy, or hormonal therapy, depending on the type and stage of the tumor.

Gastrointestinal (GI) neoplasms refer to abnormal growths in the gastrointestinal tract, which can be benign or malignant. The gastrointestinal tract includes the mouth, esophagus, stomach, small intestine, large intestine, rectum, and anus.

Benign neoplasms are non-cancerous growths that do not invade nearby tissues or spread to other parts of the body. They can sometimes be removed completely and may not cause any further health problems.

Malignant neoplasms, on the other hand, are cancerous growths that can invade nearby tissues and organs and spread to other parts of the body through the bloodstream or lymphatic system. These types of neoplasms can be life-threatening if not diagnosed and treated promptly.

GI neoplasms can cause various symptoms, including abdominal pain, bloating, changes in bowel habits, nausea, vomiting, weight loss, and anemia. The specific symptoms may depend on the location and size of the neoplasm.

There are many types of GI neoplasms, including adenocarcinomas, gastrointestinal stromal tumors (GISTs), lymphomas, and neuroendocrine tumors. The diagnosis of GI neoplasms typically involves a combination of medical history, physical examination, imaging studies, and biopsy. Treatment options may include surgery, radiation therapy, chemotherapy, targeted therapy, or immunotherapy.

Pancreatic ductal carcinoma (PDC) is a specific type of cancer that forms in the ducts that carry digestive enzymes out of the pancreas. It's the most common form of exocrine pancreatic cancer, making up about 90% of all cases.

The symptoms of PDC are often vague and can include abdominal pain, jaundice (yellowing of the skin and eyes), unexplained weight loss, and changes in bowel movements. These symptoms can be similar to those caused by other less serious conditions, which can make diagnosis difficult.

Pancreatic ductal carcinoma is often aggressive and difficult to treat. The prognosis for PDC is generally poor, with a five-year survival rate of only about 9%. Treatment options may include surgery, chemotherapy, radiation therapy, or a combination of these approaches. However, because PDC is often not detected until it has advanced, treatment is frequently focused on palliative care to relieve symptoms and improve quality of life.

Experimental neoplasms refer to abnormal growths or tumors that are induced and studied in a controlled laboratory setting, typically in animals or cell cultures. These studies are conducted to understand the fundamental mechanisms of cancer development, progression, and potential treatment strategies. By manipulating various factors such as genetic mutations, environmental exposures, and pharmacological interventions, researchers can gain valuable insights into the complex processes underlying neoplasm formation and identify novel targets for cancer therapy. It is important to note that experimental neoplasms may not always accurately represent human cancers, and further research is needed to translate these findings into clinically relevant applications.

A neoplasm of vascular tissue is an abnormal growth or mass of cells in the blood vessels or lymphatic vessels. These growths can be benign (non-cancerous) or malignant (cancerous). Benign neoplasms, such as hemangiomas and lymphangiomas, are typically not harmful and may not require treatment. However, they can cause symptoms if they grow large enough to press on nearby organs or tissues. Malignant neoplasms, such as angiosarcomas, are cancerous and can invade and destroy surrounding tissue, as well as spread (metastasize) to other parts of the body. Treatment for vascular tissue neoplasms depends on the type, size, location, and stage of the growth, and may include surgery, radiation therapy, chemotherapy, or a combination of these.

Eye neoplasms, also known as ocular tumors or eye cancer, refer to abnormal growths of tissue in the eye. These growths can be benign (non-cancerous) or malignant (cancerous). Eye neoplasms can develop in various parts of the eye, including the eyelid, conjunctiva, cornea, iris, ciliary body, choroid, retina, and optic nerve.

Benign eye neoplasms are typically slow-growing and do not spread to other parts of the body. They may cause symptoms such as vision changes, eye pain, or a noticeable mass in the eye. Treatment options for benign eye neoplasms include monitoring, surgical removal, or radiation therapy.

Malignant eye neoplasms, on the other hand, can grow and spread rapidly to other parts of the body. They may cause symptoms such as vision changes, eye pain, floaters, or flashes of light. Treatment options for malignant eye neoplasms depend on the type and stage of cancer but may include surgery, radiation therapy, chemotherapy, or a combination of these treatments.

It is important to note that early detection and treatment of eye neoplasms can improve outcomes and prevent complications. Regular eye exams with an ophthalmologist are recommended for early detection and prevention of eye diseases, including eye neoplasms.

Nose neoplasms refer to abnormal growths or tumors in the nasal cavity or paranasal sinuses. These growths can be benign (non-cancerous) or malignant (cancerous). Benign neoplasms are typically slow-growing and do not spread to other parts of the body, while malignant neoplasms can invade surrounding tissues and have the potential to metastasize.

Nose neoplasms can cause various symptoms such as nasal congestion, nosebleeds, difficulty breathing through the nose, loss of smell, facial pain or numbness, and visual changes if they affect the eye. The diagnosis of nose neoplasms usually involves a combination of physical examination, imaging studies (such as CT or MRI scans), and biopsy to determine the type and extent of the growth. Treatment options depend on the type, size, location, and stage of the neoplasm and may include surgery, radiation therapy, chemotherapy, or a combination of these approaches.

Salivary gland neoplasms refer to abnormal growths or tumors that develop in the salivary glands. These glands are responsible for producing saliva, which helps in digestion, lubrication of food and maintaining oral health. Salivary gland neoplasms can be benign (non-cancerous) or malignant (cancerous).

Benign neoplasms are slow-growing and typically do not spread to other parts of the body. They may cause symptoms such as swelling, painless lumps, or difficulty swallowing if they grow large enough to put pressure on surrounding tissues.

Malignant neoplasms, on the other hand, can be aggressive and have the potential to invade nearby structures and metastasize (spread) to distant organs. Symptoms of malignant salivary gland neoplasms may include rapid growth, pain, numbness, or paralysis of facial nerves.

Salivary gland neoplasms can occur in any of the major salivary glands (parotid, submandibular, and sublingual glands) or in the minor salivary glands located throughout the mouth and throat. The exact cause of these neoplasms is not fully understood, but risk factors may include exposure to radiation, certain viral infections, and genetic predisposition.

Radiation-induced neoplasms are a type of cancer or tumor that develops as a result of exposure to ionizing radiation. Ionizing radiation is radiation with enough energy to remove tightly bound electrons from atoms or molecules, leading to the formation of ions. This type of radiation can damage DNA and other cellular structures, which can lead to mutations and uncontrolled cell growth, resulting in the development of a neoplasm.

Radiation-induced neoplasms can occur after exposure to high levels of ionizing radiation, such as that received during radiation therapy for cancer treatment or from nuclear accidents. The risk of developing a radiation-induced neoplasm depends on several factors, including the dose and duration of radiation exposure, the type of radiation, and the individual's genetic susceptibility to radiation-induced damage.

Radiation-induced neoplasms can take many years to develop after initial exposure to ionizing radiation, and they often occur at the site of previous radiation therapy. Common types of radiation-induced neoplasms include sarcomas, carcinomas, and thyroid cancer. It is important to note that while ionizing radiation can increase the risk of developing cancer, the overall risk is still relatively low, especially when compared to other well-established cancer risk factors such as smoking and exposure to certain chemicals.

Adenocarcinoma, papillary is a type of cancer that begins in the glandular cells and grows in a finger-like projection (called a papilla). This type of cancer can occur in various organs, including the lungs, pancreas, thyroid, and female reproductive system. The prognosis and treatment options for papillary adenocarcinoma depend on several factors, such as the location and stage of the tumor, as well as the patient's overall health. It is important to consult with a healthcare professional for an accurate diagnosis and personalized treatment plan.

Carcinoma, papillary is a type of cancer that begins in the cells that line the glandular structures or the lining of organs. In a papillary carcinoma, the cancerous cells grow and form small finger-like projections, called papillae, within the tumor. This type of cancer most commonly occurs in the thyroid gland, but can also be found in other organs such as the lung, breast, and kidney. Papillary carcinoma of the thyroid gland is usually slow-growing and has a good prognosis, especially when it is diagnosed at an early stage.

Testicular neoplasms are abnormal growths or tumors in the testicle that can be benign (non-cancerous) or malignant (cancerous). They are a type of genitourinary cancer, which affects the reproductive and urinary systems. Testicular neoplasms can occur in men of any age but are most commonly found in young adults between the ages of 15 and 40.

Testicular neoplasms can be classified into two main categories: germ cell tumors and non-germ cell tumors. Germ cell tumors, which arise from the cells that give rise to sperm, are further divided into seminomas and non-seminomas. Seminomas are typically slow-growing and have a good prognosis, while non-seminomas tend to grow more quickly and can spread to other parts of the body.

Non-germ cell tumors are less common than germ cell tumors and include Leydig cell tumors, Sertoli cell tumors, and lymphomas. These tumors can have a variety of clinical behaviors, ranging from benign to malignant.

Testicular neoplasms often present as a painless mass or swelling in the testicle. Other symptoms may include a feeling of heaviness or discomfort in the scrotum, a dull ache in the lower abdomen or groin, and breast enlargement (gynecomastia).

Diagnosis typically involves a physical examination, imaging studies such as ultrasound or CT scan, and blood tests to detect tumor markers. Treatment options depend on the type and stage of the neoplasm but may include surgery, radiation therapy, chemotherapy, or a combination of these modalities. Regular self-examinations of the testicles are recommended for early detection and improved outcomes.

Neoplasms in muscle tissue refer to abnormal and excessive growths of muscle cells that can be benign or malignant. These growths can arise from any of the three types of muscle tissue: skeletal, cardiac, or smooth muscle. Neoplasms in muscle tissue are classified based on their origin, behavior, and histological features.

Benign neoplasms in muscle tissue include leiomyomas (smooth muscle), rhabdomyomas (skeletal muscle), and myxomas (cardiac muscle). These tumors are usually slow-growing and do not invade surrounding tissues or spread to other parts of the body.

Malignant neoplasms in muscle tissue, also known as sarcomas, include leiomyosarcoma (smooth muscle), rhabdomyosarcoma (skeletal muscle), and angiosarcoma (cardiac muscle). These tumors are aggressive, invasive, and have the potential to metastasize to other parts of the body.

Symptoms of neoplasms in muscle tissue depend on their location, size, and type. They may include a painless or painful mass, weakness, fatigue, weight loss, and difficulty swallowing or breathing. Treatment options for neoplasms in muscle tissue include surgery, radiation therapy, chemotherapy, and targeted therapy. The choice of treatment depends on the type, stage, location, and patient's overall health condition.

Neoplasms are abnormal growths of cells or tissues that serve no purpose and can be benign (non-cancerous) or malignant (cancerous). Glandular and epithelial neoplasms refer to specific types of tumors that originate from the glandular and epithelial tissues, respectively.

Glandular neoplasms arise from the glandular tissue, which is responsible for producing and secreting substances such as hormones, enzymes, or other fluids. These neoplasms can be further classified into adenomas (benign) and adenocarcinomas (malignant).

Epithelial neoplasms, on the other hand, develop from the epithelial tissue that lines the outer surfaces of organs and the inner surfaces of cavities. These neoplasms can also be benign or malignant and are classified as papillomas (benign) and carcinomas (malignant).

It is important to note that while both glandular and epithelial neoplasms can become cancerous, not all of them do. However, if they do, the malignant versions can invade surrounding tissues and spread to other parts of the body, making them potentially life-threatening.

Mucinous cystadenocarcinoma is a type of cancer that arises from the mucin-producing cells in the lining of a cyst. It is a subtype of cystadenocarcinoma, which is a malignant tumor that develops within a cyst. Mucinous cystadenocarcinomas are typically found in the ovary or pancreas but can also occur in other organs such as the appendix and the respiratory tract.

These tumors are characterized by the production of large amounts of mucin, a gel-like substance that can accumulate within the cyst and cause it to grow. Mucinous cystadenocarcinomas tend to grow slowly but can become quite large and may eventually spread (metastasize) to other parts of the body if left untreated.

Symptoms of mucinous cystadenocarcinoma depend on the location and size of the tumor, but they may include abdominal pain or discomfort, bloating, changes in bowel movements, or vaginal bleeding. Treatment typically involves surgical removal of the tumor, followed by chemotherapy or radiation therapy to kill any remaining cancer cells. The prognosis for mucinous cystadenocarcinoma depends on several factors, including the stage of the disease at diagnosis and the patient's overall health.

An adenoma is a benign (noncancerous) tumor that develops from glandular epithelial cells. These types of cells are responsible for producing and releasing fluids, such as hormones or digestive enzymes, into the surrounding tissues. Adenomas can occur in various organs and glands throughout the body, including the thyroid, pituitary, adrenal, and digestive systems.

Depending on their location, adenomas may cause different symptoms or remain asymptomatic. Some common examples of adenomas include:

1. Colorectal adenoma (also known as a polyp): These growths occur in the lining of the colon or rectum and can develop into colorectal cancer if left untreated. Regular screenings, such as colonoscopies, are essential for early detection and removal of these polyps.
2. Thyroid adenoma: This type of adenoma affects the thyroid gland and may result in an overproduction or underproduction of hormones, leading to conditions like hyperthyroidism (overactive thyroid) or hypothyroidism (underactive thyroid).
3. Pituitary adenoma: These growths occur in the pituitary gland, which is located at the base of the brain and controls various hormonal functions. Depending on their size and location, pituitary adenomas can cause vision problems, headaches, or hormonal imbalances that affect growth, reproduction, and metabolism.
4. Liver adenoma: These rare benign tumors develop in the liver and may not cause any symptoms unless they become large enough to press on surrounding organs or structures. In some cases, liver adenomas can rupture and cause internal bleeding.
5. Adrenal adenoma: These growths occur in the adrenal glands, which are located above the kidneys and produce hormones that regulate stress responses, metabolism, and blood pressure. Most adrenal adenomas are nonfunctioning, meaning they do not secrete excess hormones. However, functioning adrenal adenomas can lead to conditions like Cushing's syndrome or Conn's syndrome, depending on the type of hormone being overproduced.

It is essential to monitor and manage benign tumors like adenomas to prevent potential complications, such as rupture, bleeding, or hormonal imbalances. Treatment options may include surveillance with imaging studies, medication to manage hormonal issues, or surgical removal of the tumor in certain cases.

Soft tissue neoplasms refer to abnormal growths or tumors that develop in the soft tissues of the body. Soft tissues include muscles, tendons, ligaments, fascia, nerves, blood vessels, fat, and synovial membranes (the thin layer of cells that line joints and tendons). Neoplasms can be benign (non-cancerous) or malignant (cancerous), and their behavior and potential for spread depend on the specific type of neoplasm.

Benign soft tissue neoplasms are typically slow-growing, well-circumscribed, and rarely spread to other parts of the body. They can often be removed surgically with a low risk of recurrence. Examples of benign soft tissue neoplasms include lipomas (fat tumors), schwannomas (nerve sheath tumors), and hemangiomas (blood vessel tumors).

Malignant soft tissue neoplasms, on the other hand, can grow rapidly, invade surrounding tissues, and may metastasize (spread) to distant parts of the body. They are often more difficult to treat than benign neoplasms and require a multidisciplinary approach, including surgery, radiation therapy, and chemotherapy. Examples of malignant soft tissue neoplasms include sarcomas, such as rhabdomyosarcoma (arising from skeletal muscle), leiomyosarcoma (arising from smooth muscle), and angiosarcoma (arising from blood vessels).

It is important to note that soft tissue neoplasms can occur in any part of the body, and their diagnosis and treatment require a thorough evaluation by a healthcare professional with expertise in this area.

Hematologic neoplasms, also known as hematological malignancies, are a group of diseases characterized by the uncontrolled growth and accumulation of abnormal blood cells or bone marrow cells. These disorders can originate from the myeloid or lymphoid cell lines, which give rise to various types of blood cells, including red blood cells, white blood cells, and platelets.

Hematologic neoplasms can be broadly classified into three categories:

1. Leukemias: These are cancers that primarily affect the bone marrow and blood-forming tissues. They result in an overproduction of abnormal white blood cells, which interfere with the normal functioning of the blood and immune system. There are several types of leukemia, including acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), and chronic myeloid leukemia (CML).
2. Lymphomas: These are cancers that develop from the lymphatic system, which is a part of the immune system responsible for fighting infections. Lymphomas can affect lymph nodes, spleen, bone marrow, and other organs. The two main types of lymphoma are Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL).
3. Myelomas: These are cancers that arise from the plasma cells, a type of white blood cell responsible for producing antibodies. Multiple myeloma is the most common type of myeloma, characterized by an excessive proliferation of malignant plasma cells in the bone marrow, leading to the production of abnormal amounts of monoclonal immunoglobulins (M proteins) and bone destruction.

Hematologic neoplasms can have various symptoms, such as fatigue, weakness, frequent infections, easy bruising or bleeding, weight loss, swollen lymph nodes, and bone pain. The diagnosis typically involves a combination of medical history, physical examination, laboratory tests, imaging studies, and sometimes bone marrow biopsy. Treatment options depend on the type and stage of the disease and may include chemotherapy, radiation therapy, targeted therapy, immunotherapy, stem cell transplantation, or a combination of these approaches.

A neoplasm is a tumor or growth that is formed by an abnormal and excessive proliferation of cells, which can be benign or malignant. Neoplasm proteins are therefore any proteins that are expressed or produced in these neoplastic cells. These proteins can play various roles in the development, progression, and maintenance of neoplasms.

Some neoplasm proteins may contribute to the uncontrolled cell growth and division seen in cancer, such as oncogenic proteins that promote cell cycle progression or inhibit apoptosis (programmed cell death). Others may help the neoplastic cells evade the immune system, allowing them to proliferate undetected. Still others may be involved in angiogenesis, the formation of new blood vessels that supply the tumor with nutrients and oxygen.

Neoplasm proteins can also serve as biomarkers for cancer diagnosis, prognosis, or treatment response. For example, the presence or level of certain neoplasm proteins in biological samples such as blood or tissue may indicate the presence of a specific type of cancer, help predict the likelihood of cancer recurrence, or suggest whether a particular therapy will be effective.

Overall, understanding the roles and behaviors of neoplasm proteins can provide valuable insights into the biology of cancer and inform the development of new diagnostic and therapeutic strategies.

Uterine neoplasms refer to abnormal growths in the uterus, which can be benign (non-cancerous) or malignant (cancerous). These growths can originate from different types of cells within the uterus, leading to various types of uterine neoplasms. The two main categories of uterine neoplasms are endometrial neoplasms and uterine sarcomas.

Endometrial neoplasms develop from the endometrium, which is the inner lining of the uterus. Most endometrial neoplasms are classified as endometrioid adenocarcinomas, arising from glandular cells in the endometrium. Other types include serous carcinoma, clear cell carcinoma, and mucinous carcinoma.

Uterine sarcomas, on the other hand, are less common and originate from the connective tissue (stroma) or muscle (myometrium) of the uterus. Uterine sarcomas can be further divided into several subtypes, such as leiomyosarcoma, endometrial stromal sarcoma, and undifferentiated uterine sarcoma.

Uterine neoplasms can cause various symptoms, including abnormal vaginal bleeding or discharge, pelvic pain, and difficulty urinating or having bowel movements. The diagnosis typically involves a combination of imaging tests (such as ultrasound, CT, or MRI scans) and tissue biopsies to determine the type and extent of the neoplasm. Treatment options depend on the type, stage, and patient's overall health but may include surgery, radiation therapy, chemotherapy, or hormone therapy.

Intestinal neoplasms refer to abnormal growths in the tissues of the intestines, which can be benign or malignant. These growths are called neoplasms and they result from uncontrolled cell division. In the case of intestinal neoplasms, these growths occur in the small intestine, large intestine (colon), rectum, or appendix.

Benign intestinal neoplasms are not cancerous and often do not invade surrounding tissues or spread to other parts of the body. However, they can still cause problems if they grow large enough to obstruct the intestines or cause bleeding. Common types of benign intestinal neoplasms include polyps, leiomyomas, and lipomas.

Malignant intestinal neoplasms, on the other hand, are cancerous and can invade surrounding tissues and spread to other parts of the body. The most common type of malignant intestinal neoplasm is adenocarcinoma, which arises from the glandular cells lining the inside of the intestines. Other types of malignant intestinal neoplasms include lymphomas, sarcomas, and carcinoid tumors.

Symptoms of intestinal neoplasms can vary depending on their size, location, and type. Common symptoms include abdominal pain, bloating, changes in bowel habits, rectal bleeding, weight loss, and fatigue. If you experience any of these symptoms, it is important to seek medical attention promptly.

Neoplasms, adnexal and skin appendage refer to abnormal growths or tumors that develop in the sweat glands, hair follicles, or other structures associated with the skin. These growths can be benign (non-cancerous) or malignant (cancerous), and they can occur anywhere on the body.

Adnexal neoplasms are tumors that arise from the sweat glands or hair follicles, including the sebaceous glands, eccrine glands, and apocrine glands. These tumors can range in size and severity, and they may cause symptoms such as pain, itching, or changes in the appearance of the skin.

Skin appendage neoplasms are similar to adnexal neoplasms, but they specifically refer to tumors that arise from structures such as hair follicles, nails, and sweat glands. Examples of skin appendage neoplasms include pilomatricomas (tumors of the hair follicle), trichilemmomas (tumors of the outer root sheath of the hair follicle), and sebaceous adenomas (tumors of the sebaceous glands).

It is important to note that while many adnexal and skin appendage neoplasms are benign, some can be malignant and may require aggressive treatment. If you notice any unusual growths or changes in your skin, it is important to consult with a healthcare professional for further evaluation and care.

Vascular neoplasms are a type of tumor that develops from cells that line the blood vessels or lymphatic vessels. These tumors can be benign (non-cancerous) or malignant (cancerous). Benign vascular neoplasms, such as hemangiomas and lymphangiomas, are usually harmless and may not require treatment unless they cause symptoms or complications. Malignant vascular neoplasms, on the other hand, are known as angiosarcomas and can be aggressive, spreading to other parts of the body and potentially causing serious health problems.

Angiosarcomas can develop in any part of the body but are most commonly found in the skin, particularly in areas exposed to radiation or chronic lymph edema. They can also occur in the breast, liver, spleen, and heart. Treatment for vascular neoplasms depends on the type, location, size, and stage of the tumor, as well as the patient's overall health. Treatment options may include surgery, radiation therapy, chemotherapy, or a combination of these approaches.

Sweat gland neoplasms are abnormal growths that develop in the sweat glands. These growths can be benign (noncancerous) or malignant (cancerous). Benign sweat gland neoplasms include hidradenomas and syringomas, which are usually slow-growing and cause little to no symptoms. Malignant sweat gland neoplasms, also known as sweat gland carcinomas, are rare but aggressive cancers that can spread to other parts of the body. They may cause symptoms such as a lump or mass under the skin, pain, swelling, and redness. Treatment typically involves surgical removal of the growth.

Lymphoma is a type of cancer that originates from the white blood cells called lymphocytes, which are part of the immune system. These cells are found in various parts of the body such as the lymph nodes, spleen, bone marrow, and other organs. Lymphoma can be classified into two main types: Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL).

HL is characterized by the presence of a specific type of abnormal lymphocyte called Reed-Sternberg cells, while NHL includes a diverse group of lymphomas that lack these cells. The symptoms of lymphoma may include swollen lymph nodes, fever, night sweats, weight loss, and fatigue.

The exact cause of lymphoma is not known, but it is believed to result from genetic mutations in the lymphocytes that lead to uncontrolled cell growth and division. Exposure to certain viruses, chemicals, and radiation may increase the risk of developing lymphoma. Treatment options for lymphoma depend on various factors such as the type and stage of the disease, age, and overall health of the patient. Common treatments include chemotherapy, radiation therapy, immunotherapy, and stem cell transplantation.

Bone neoplasms are abnormal growths or tumors that develop in the bone. They can be benign (non-cancerous) or malignant (cancerous). Benign bone neoplasms do not spread to other parts of the body and are rarely a threat to life, although they may cause problems if they grow large enough to press on surrounding tissues or cause fractures. Malignant bone neoplasms, on the other hand, can invade and destroy nearby tissue and may spread (metastasize) to other parts of the body.

There are many different types of bone neoplasms, including:

1. Osteochondroma - a benign tumor that develops from cartilage and bone
2. Enchondroma - a benign tumor that forms in the cartilage that lines the inside of the bones
3. Chondrosarcoma - a malignant tumor that develops from cartilage
4. Osteosarcoma - a malignant tumor that develops from bone cells
5. Ewing sarcoma - a malignant tumor that develops in the bones or soft tissues around the bones
6. Giant cell tumor of bone - a benign or occasionally malignant tumor that develops from bone tissue
7. Fibrosarcoma - a malignant tumor that develops from fibrous tissue in the bone

The symptoms of bone neoplasms vary depending on the type, size, and location of the tumor. They may include pain, swelling, stiffness, fractures, or limited mobility. Treatment options depend on the type and stage of the tumor but may include surgery, radiation therapy, chemotherapy, or a combination of these treatments.

Palatal neoplasms refer to abnormal growths or tumors that occur on the palate, which is the roof of the mouth. These growths can be benign (non-cancerous) or malignant (cancerous). Benign neoplasms are typically slower growing and less likely to spread, while malignant neoplasms are more aggressive and can invade nearby tissues and organs.

Palatal neoplasms can have various causes, including genetic factors, environmental exposures, and viral infections. They may present with symptoms such as mouth pain, difficulty swallowing, swelling or lumps in the mouth, bleeding, or numbness in the mouth or face.

The diagnosis of palatal neoplasms typically involves a thorough clinical examination, imaging studies, and sometimes biopsy to determine the type and extent of the growth. Treatment options depend on the type, size, location, and stage of the neoplasm but may include surgery, radiation therapy, chemotherapy, or a combination of these approaches. Regular follow-up care is essential to monitor for recurrence or spread of the neoplasm.

Neoplasms are abnormal growths of cells or tissues in the body that can be benign (non-cancerous) or malignant (cancerous). When referring to "Complex and Mixed Neoplasms," it is typically used in the context of histopathology, where it describes tumors with a mixture of different types of cells or growth patterns.

A complex neoplasm usually contains areas with various architectural patterns, cell types, or both, making its classification challenging. It may require extensive sampling and careful examination to determine its nature and behavior. These neoplasms can be either benign or malignant, depending on the specific characteristics of the tumor cells and their growth pattern.

A mixed neoplasm, on the other hand, is a tumor that contains more than one type of cell or tissue component, often arising from different germ layers (the three primary layers of embryonic development: ectoderm, mesoderm, and endoderm). A common example of a mixed neoplasm is a teratoma, which can contain tissues derived from all three germ layers, such as skin, hair, teeth, bone, and muscle. Mixed neoplasms can also be benign or malignant, depending on the specific components of the tumor.

It's important to note that the classification and behavior of complex and mixed neoplasms can vary significantly based on their location in the body, cellular composition, and other factors. Accurate diagnosis typically requires a thorough examination by an experienced pathologist and may involve additional tests, such as immunohistochemistry or molecular analysis, to determine the appropriate treatment and management strategies.

Neoplasm antigens, also known as tumor antigens, are substances that are produced by cancer cells (neoplasms) and can stimulate an immune response. These antigens can be proteins, carbohydrates, or other molecules that are either unique to the cancer cells or are overexpressed or mutated versions of normal cellular proteins.

Neoplasm antigens can be classified into two main categories: tumor-specific antigens (TSAs) and tumor-associated antigens (TAAs). TSAs are unique to cancer cells and are not expressed by normal cells, while TAAs are present at low levels in normal cells but are overexpressed or altered in cancer cells.

TSAs can be further divided into viral antigens and mutated antigens. Viral antigens are produced when cancer is caused by a virus, such as human papillomavirus (HPV) in cervical cancer. Mutated antigens are the result of genetic mutations that occur during cancer development and are unique to each patient's tumor.

Neoplasm antigens play an important role in the immune response against cancer. They can be recognized by the immune system, leading to the activation of immune cells such as T cells and natural killer (NK) cells, which can then attack and destroy cancer cells. However, cancer cells often develop mechanisms to evade the immune response, allowing them to continue growing and spreading.

Understanding neoplasm antigens is important for the development of cancer immunotherapies, which aim to enhance the body's natural immune response against cancer. These therapies include checkpoint inhibitors, which block proteins that inhibit T cell activation, and therapeutic vaccines, which stimulate an immune response against specific tumor antigens.

Mandibular neoplasms refer to abnormal growths or tumors that develop in the mandible, which is the lower jawbone. These growths can be benign (non-cancerous) or malignant (cancerous). Benign neoplasms are typically slow-growing and rarely spread to other parts of the body, while malignant neoplasms can invade surrounding tissues and may metastasize (spread) to distant sites.

Mandibular neoplasms can have various causes, including genetic mutations, exposure to certain chemicals or radiation, and infection with certain viruses. The symptoms of mandibular neoplasms may include swelling or pain in the jaw, difficulty chewing or speaking, numbness in the lower lip or chin, loose teeth, and/or a lump or mass in the mouth or neck.

The diagnosis of mandibular neoplasms typically involves a thorough clinical examination, imaging studies such as X-rays, CT scans, or MRI scans, and sometimes a biopsy to confirm the type and extent of the tumor. Treatment options depend on the type, stage, and location of the neoplasm, and may include surgery, radiation therapy, chemotherapy, or a combination of these approaches. Regular follow-up care is essential to monitor for recurrence or metastasis.

Bile duct neoplasms, also known as cholangiocarcinomas, refer to a group of malignancies that arise from the bile ducts. These are the tubes that carry bile from the liver to the gallbladder and small intestine. Bile duct neoplasms can be further classified based on their location as intrahepatic (within the liver), perihilar (at the junction of the left and right hepatic ducts), or distal (in the common bile duct).

These tumors are relatively rare, but their incidence has been increasing in recent years. They can cause a variety of symptoms, including jaundice, abdominal pain, weight loss, and fever. The diagnosis of bile duct neoplasms typically involves imaging studies such as CT or MRI scans, as well as blood tests to assess liver function. In some cases, a biopsy may be necessary to confirm the diagnosis.

Treatment options for bile duct neoplasms depend on several factors, including the location and stage of the tumor, as well as the patient's overall health. Surgical resection is the preferred treatment for early-stage tumors, while chemotherapy and radiation therapy may be used in more advanced cases. For patients who are not candidates for surgery, palliative treatments such as stenting or bypass procedures may be recommended to relieve symptoms and improve quality of life.

Neoplasm invasiveness is a term used in pathology and oncology to describe the aggressive behavior of cancer cells as they invade surrounding tissues and organs. This process involves the loss of cell-to-cell adhesion, increased motility and migration, and the ability of cancer cells to degrade the extracellular matrix (ECM) through the production of enzymes such as matrix metalloproteinases (MMPs).

Invasive neoplasms are cancers that have spread beyond the original site where they first developed and have infiltrated adjacent tissues or structures. This is in contrast to non-invasive or in situ neoplasms, which are confined to the epithelial layer where they originated and have not yet invaded the underlying basement membrane.

The invasiveness of a neoplasm is an important prognostic factor in cancer diagnosis and treatment, as it can indicate the likelihood of metastasis and the potential effectiveness of various therapies. In general, more invasive cancers are associated with worse outcomes and require more aggressive treatment approaches.

Thymus neoplasms are abnormal growths in the thymus gland that result from uncontrolled cell division. The term "neoplasm" refers to any new and abnormal growth of tissue, also known as a tumor. Thymus neoplasms can be benign or malignant (cancerous).

Malignant thymus neoplasms are called thymomas or thymic carcinomas. Thymomas are the most common type and tend to grow slowly, invading nearby tissues and organs. They can also spread (metastasize) to other parts of the body. Thymic carcinomas are rarer and more aggressive, growing and spreading more quickly than thymomas.

Symptoms of thymus neoplasms may include coughing, chest pain, difficulty breathing, or swelling in the neck or upper chest. Treatment options for thymus neoplasms depend on the type, size, location, and stage of the tumor, as well as the patient's overall health. Treatment may include surgery, radiation therapy, chemotherapy, or a combination of these approaches.

Splenic neoplasms refer to abnormal growths or tumors in the spleen, which can be benign (non-cancerous) or malignant (cancerous). These growths can arise from various cell types present within the spleen, including hematopoietic cells (red and white blood cells, platelets), stromal cells (supporting tissue), or lymphoid cells (part of the immune system).

There are several types of splenic neoplasms:

1. Hematologic malignancies: These are cancers that affect the blood and bone marrow, such as leukemias, lymphomas, and multiple myeloma. They often involve the spleen, causing enlargement (splenomegaly) and neoplastic infiltration of splenic tissue.
2. Primary splenic tumors: These are rare and include benign lesions like hemangiomas, lymphangiomas, and hamartomas, as well as malignant tumors such as angiosarcoma, littoral cell angiosarcoma, and primary splenic lymphoma.
3. Metastatic splenic tumors: These occur when cancer cells from other primary sites spread (metastasize) to the spleen. Common sources of metastasis include lung, breast, colon, and ovarian cancers, as well as melanomas and sarcomas.

Symptoms of splenic neoplasms may vary depending on the type and extent of the disease but often include abdominal pain or discomfort, fatigue, weight loss, and anemia. Diagnosis typically involves imaging studies (such as ultrasound, CT, or MRI scans) and sometimes requires a biopsy for confirmation. Treatment options depend on the type of neoplasm and may include surgery, chemotherapy, radiation therapy, targeted therapy, or immunotherapy.

Heart neoplasms are abnormal growths or tumors that develop within the heart tissue. They can be benign (noncancerous) or malignant (cancerous). Benign tumors, such as myxomas and rhabdomyomas, are typically slower growing and less likely to spread, but they can still cause serious complications if they obstruct blood flow or damage heart valves. Malignant tumors, such as angiosarcomas and rhabdomyosarcomas, are fast-growing and have a higher risk of spreading to other parts of the body. Symptoms of heart neoplasms can include shortness of breath, chest pain, fatigue, and irregular heart rhythms. Treatment options depend on the type, size, and location of the tumor, and may include surgery, radiation therapy, or chemotherapy.

Ovarian Neoplasm Imaging. Springer Science & Business Media. p. 165. ISBN 9781461486336. "NCI Dictionary of Cancer Terms". ... Ovarian teratomas represent about a quarter of ovarian tumors and are typically noticed during middle age. Testicular teratomas ... Treatment of coccyx, testicular, and ovarian teratomas is generally by surgery. Testicular and immature ovarian teratomas are ... Ovarian teratomas often present with abdominal or pelvic pain, caused by torsion of the ovary or irritation of its ligaments. A ...
... is the most common ovarian neoplasm, representing 20% of ovarian neoplasms, and is benign. It has a very superficial ... "Common Causes of Ovarian Enlargement: Ovarian neoplasms". Human Reproduction. University of Utah Medpath. Cheng EJ, Kurman RJ, ... resembling ovarian surface epithelium Ovarian serous cystadenoma accounts for the largest proportion of benign ovarian tumours ... Serous ovarian cystadenocarcinomas account for ~25% of serous tumours. Ovarian cancer Pancreatic serous cystadenoma Serous ...
The ovarian fibroma, also fibroma, is a benign sex cord-stromal tumour. Ovarian fibromas represent 4% of all ovarian neoplasms ... There may be thecomatous areas (fibrothecoma). The presence of an ovarian fibroma can cause ovarian torsion in some cases. ... Vaidya, SA; Kc, S; Sharma, P; Vaidya, S (2014). "Spectrum of ovarian tumors in a referral hospital in Nepal". Journal of ... Diagnosis is usually made by ultrasonography showing a solid ovarian lesion, or, on some occasions, mixed tumors with solid and ...
Sachdeva P, Arora R, Dubey C, Sukhija A, Daga M, Singh DK (April 2008). "Sertoli-Leydig cell tumor: a rare ovarian neoplasm. ... Animal studies a suggest possible link with C8 (C8HF15O2, perfluorooctanoic acid). Presence of an ovarian tumour plus hormonal ... is a member of the sex cord-stromal tumour group of ovarian and testicular cancers. It arises from Leydig cells. While the ... Ovarian cancer, Male genital neoplasia, Rare cancers, Endocrine neoplasia, Endocrine-related cutaneous conditions). ...
Relative frequency of primary ovarian neoplasms: a 10-year review. Obstet Gynecol 1989; 74:921. Magrina JF, Espada M, Munoz R, ... In premenopausal women, adnexal masses include ovarian cysts, ectopic (tubal) pregnancies, benign (noncancerous) or malignant ( ... cancerous) tumors, endometriomas, polycystic ovaries, and tubo-ovarian abscess. The most common causes for adnexal masses in ...
... s, or ovarian neoplasms, are tumors arising from the ovary. They can be benign or malignant (ovarian cancer). They ... Ovarian tumors are classified according to the histology of the tumor, obtained in a pathology report. Histology dictates many ... Vaidya, SA; Kc, S; Sharma, P; Vaidya, S (2014). "Spectrum of ovarian tumors in a referral hospital in Nepal". Journal of ... Unless otherwise specified in boxes, reference is: Vaidya, SA; Kc, S; Sharma, P; Vaidya, S (2014). "Spectrum of ovarian tumors ...
Kim, Mi Suk; Park, Soyoon; Lee, Tae Sung (April 2002). "Old abdominal pregnancy presenting as an ovarian neoplasm". Journal of ... Lithopedia can originate both as tubal and ovarian pregnancies, although tubal pregnancy cases are more common. * After death ... following the rupture of the placental and ovarian membranes; and Lithokelyphopedion ("Stone Sheath [and] Child"), where both ...
A rare ovarian neoplasm. Case report and review of literature". Gynecological Endocrinology. 24 (4): 230-4. doi:10.1080/ ... is a testosterone-secreting ovarian tumor and is a member of the sex cord-stromal tumour group of ovarian and testicular ... Presence of an ovarian tumour plus hormonal disturbances suggests a Sertoli-Leydig cell tumour. However, hormonal disturbance ... "DICER1 Mutations in Familial Multinodular Goiter With and Without Ovarian Sertoli-Leydig Cell Tumors". JAMA. 305 (1): 68-77. ...
It appears in the sex cord-stromal tumour group of ovarian neoplasms. Ovary fibromas are most frequent during middle age, and ... There may be thecomatous areas (fibrothecoma). The presence of an ovarian fibroma can cause ovarian torsion in some cases. ...
... s or theca cell tumors are benign ovarian neoplasms composed only of theca cells. Histogenetically they are classified ... October 2004). "Ovarian thecoma associated in the first trimester of pregnancy". J. Obstet. Gynaecol. Res. 30 (5): 368-71. doi: ... Grossly and microscopically, it consists of the ovarian cortex. Microscopically, the tumour cells have abundant lipid-filled ...
... in ovarian neoplasms predicts shorter survival". Human Pathology. 28 (6): 686-692. doi:10.1016/S0046-8177(97)90177-5. PMID ...
"Pancreatic mucinous cystic neoplasm defined by ovarian stroma: demographics, clinical features, and prevalence of cancer". ... Pancreatic mucinous cystic neoplasm (MCN) is a type of cystic lesion that occurs in the pancreas. Amongst individuals ... Intraductal papillary mucinous neoplasm Pancreatic serous cystadenoma Elta, GH; Enestvedt, BK; Sauer, BG; Lennon, AM (April ... Histologic evaluation of MCNs shows mucin-producing columnar epithelial lining, which is surrounded by ovarian-like stroma. ...
"Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens in serous ovarian neoplasms". Clinical Cancer Research. 9 (17): ...
2009). "Guanylyl cyclase C is a specific marker for differentiating primary and metastatic ovarian mucinous neoplasms". ...
... s are an uncommon subtype of the surface epithelial-stromal tumour group of ovarian neoplasms. The majority are ... Histologically, Leydig cell tumours of the testes and ovarian stromal Leydig cell tumours (ovarian hyperandrogenism and ... The coffee bean nuclei are the nuclear grooves exceptionally pathognomonic to the sex cord stromal tumour, the ovarian ... Histology at University of Utah (Articles with short description, Short description is different from Wikidata, Ovarian cancer) ...
... s are a class of ovarian neoplasms that may be benign or malignant. Neoplasms in this group are ... One rare but noteworthy condition associated with mucinous ovarian neoplasms is pseudomyxoma peritonei. As primary ovarian ... For more general information, see ovarian cancer. Research suggests that in the first line treatment of Endometrial Ovarian ... of all ovarian neoplasms In some cases mucinous tumors are characterized by more cysts of variable size and a rarity of surface ...
Sertoli-Leydig cell tumour is part of the sex cord-stromal tumour group of ovarian neoplasms. These tumors produce both Sertoli ...
Laparoscopy may be an option if the surgeon is particularly skilled in removing ovarian neoplasms via laparoscopy intact. If ... A gonadoblastoma is a complex neoplasm composed of a mixture of gonadal elements, such as large primordial germ cells, immature ...
Immunohistochemistry may help in diagnosing Krukenberg tumors from primary ovarian neoplasms but needs to be applied with ... In most countries, cancer that has metastasized to the ovary accounts for only about 1 to 2% of ovarian cancer; in the ... Krukenberg tumors can occasionally provoke a reaction of the ovarian stroma which leads to hormone production, that results in ... Papakonstantinou E, Liapis A, Kairi-Vassilatou E, Iavazzo C, Kleanthis CK, Kondi-Pafiti A (2011). "Virilizing ovarian ...
Two types are recognized: serous and mucinous.Ovarian cystadenomas are common benign epithelial neoplasms that carry an ... Ovarian cystadenoma is a cystic benign tumor of the ovary. ... Ovarian cancer, All stub articles, Neoplasm stubs). ... Limaiem, Faten; Lekkala, Manidhar Reddy; Mlika, Mouna (2022), "Ovarian Cystadenoma", StatPearls, Treasure Island (FL): ... Limaiem, Faten; Mlika, Mouna (2019). "Ovarian Cystadenoma". StatPearls. StatPearls Publishing. Retrieved 21 November 2019. ...
They are part of the surface epithelial tumor group of ovarian neoplasms (10-20% of which are the endometrioid type). Benign ... Ovarian and endometrial endometrioid carcinomas have distinct CTNNB1 and PTEN gene mutation profiles. PTEN mutations are more ... "Ovarian and endometrial endometrioid carcinomas have distinct CTNNB1 and PTEN mutation profiles". Modern Pathology. 27 (1): 128 ... CTNNB1 mutations are significantly different in low-grade ovarian endometrioid carcinomas (53%) compared with low-grade ...
Of solid tumor neoplasms, ovarian cancer is most likely to provoke eosinophilia, though any other cancer can cause the ... The World Health Organization classifies these disorders into a) Myeloid and lymphoid neoplasms with eosinophilia and ... Reiter A, Gotlib J (2017). "Myeloid neoplasms with eosinophilia". Blood. 129 (6): 704-714. doi:10.1182/blood-2016-10-695973. ...
... trophoblastic neoplasms, and ovarian carcinoma. Moreover, it also has been used as an immunosuppressive drug for various ...
"A case of ovarian metastasis of gallbladder carcinoma simulating primary ovarian neoplasm: diagnostic pitfalls and review of ... ovarian stroma and testis. The NCI Thesaurus identifies the following types of signet ring cell Castration cell, a non- ...
... ovarian neoplasms (malignant or benign), and peritoneal effusions. Atypical mesothelial hyperplasia Herbert, Ronald A.; ... Peritoneal mesothelial hyperplasia can be encountered in inflammatory pelvic disease with tubo-ovarian abscess, ...
Mucinous tumors are part of the surface epithelial-stromal tumor group of ovarian neoplasms, and account for approximately 36% ... Ovarian Cancer. In: Pharmacotherapy: A pathophysiologic approach.8th ed. Dipiro JT, Talbert RL, Yee GC et al., New York: McGraw ... It is well documented that malignancy may be only focally present in mucinous neoplasms of the ovary, so thorough sampling is ... Pseudomyxoma peritonei may present as a result of an ovarian mucinous tumor, however this is a rare cause of this condition, ...
This includes Wilms tumor, rhabdomyosarcoma, Ewing's sarcoma, trophoblastic neoplasm, testicular cancer, and certain types of ... ovarian cancer. It is given by injection into a vein. Most people develop side effects. Common side effects include bone marrow ...
Ovarian serous cystadenoma Pancreatic mucinous cystadenoma Solid pseudopapillary neoplasm Jais B, Rebours V, Malleo G, Salvia R ... mixed serous-endocrine neoplasm, and VHL-associated serous cystic neoplasm. This latter classification scheme is useful because ... Serous cystic neoplasms that have spread ("metastasized") to another organ are considered malignant and are designated "serous ... In contrast to some of the other cyst-forming tumors of the pancreas (such as the intraductal papillary mucinous neoplasm and ...
They can develop further into a variety of other neoplasms, including choriocarcinoma, yolk sac tumor, and teratoma. They occur ... Ovarian clear-cell carcinoma is a rare subtype of epithelial ovarian cancer. Those diagnosed with ovarian clear-cell carcinoma ... of hereditary epithelial ovarian cancer. Serous ovarian cancer is the most common type of epithelial ovarian cancer and it ... The Risk of Ovarian Malignancy algorithm uses CA-125 levels and HE4 levels to calculate the risk of ovarian cancer; it may be ...
These epigenetic defects occurred in various cancers (e.g. breast, ovarian, colorectal and head and neck). Two or three ... ICD-10 classifies neoplasms into four main groups: benign neoplasms, in situ neoplasms, malignant neoplasms, and neoplasms of ... The word neoplasm is from Ancient Greek νέος- neo 'new' and πλάσμα plasma 'formation, creation'. A neoplasm can be benign, ... The process that occurs to form or produce a neoplasm is called neoplasia. The growth of a neoplasm is uncoordinated with that ...
... suggest that platinum-based adjuvant chemotherapy improves survival and delays recurrence in patients with early-stage ovarian ... International Collaborative Ovarian Neoplasm trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ... ovarian cancer J Natl Cancer Inst. 2003 Jan 15;95(2):125-32. doi: 10.1093/jnci/95.2.125. ... question of whether platinum-based adjuvant chemotherapy can improve outcomes in patients with early-stage epithelial ovarian ...
The E2 and P4 levels in peripheral and ovarian venous blood were measured in 45 postemenopausal women with ovarian neoplasms. ... Ovarian neoplasm / FSH / LH / Receptor / ゴナドトロピン. Research Abstract. The binding of human follicle-stimulating hormone (hFSH) ... Publications] Yamoto M: Gonadotropin receptors in human ovarian neoplasms. Adv Obstet Gynecol. 45. 175-181 (1993). *. ... Publications] Nakano R: Localization of gonadotropin binding sites in human ovarian neoplasms Am J Obstet Gynecol. 161. 183- ...
The Chicago Consensus on Peritoneal Surface Malignancies: Management of Ovarian Neoplasms. Annals of surgical oncology. 2020 ... The Chicago Consensus on Peritoneal Surface Malignancies : Management of Ovarian Neoplasms. In: Annals of surgical oncology. ... The Chicago Consensus on Peritoneal Surface Malignancies: Management of Ovarian Neoplasms. / Chicago Consensus Working Group. ... Dive into the research topics of The Chicago Consensus on Peritoneal Surface Malignancies: Management of Ovarian Neoplasms. ...
Mucinous cystic neoplasms (MCNs) of the pancreas are uncommon, and their diagnosis, treatment, and prognosis have yet to be ... mucinous cystic neoplasm with ovarian stroma (MCN), and solid pseudopapillary epithelial neoplasm. IPMN is further subdivided ... Mucinous cystic neoplasm with ovarian stroma (MCN). MCNs are common in middle-aged women, are usually well defined, and are ... A foregut cystic neoplasm with diagnostic and therapeutic similarities to mucinous cystic neoplasms of the pancreas. JOP. 2013 ...
ISGyP LiVE Journal Club - Ovarian Serous Neoplasms. October 21, 2020. This content is restricted to site members. If you are an ...
Ovarian cancer is hard to detect early because it may not cause early signs or symptoms. Its important to recognize the signs ... ClinicalTrials.gov: Ovarian Neoplasms (National Institutes of Health) * ClinicalTrials.gov: Peritoneal Neoplasms (National ... Ovarian cancer: MedlinePlus Genetics (National Library of Medicine) * What Causes Ovarian Cancer? (American Cancer Society) ... Ovarian Cancer Risk Factors (American Cancer Society) Also in Spanish * Ovarian, Fallopian Tube, and Primary Peritoneal Cancer ...
Steroidogenesis in ovarian-like mesenchymal stroma of hepatic and pancreatic mucinous cystic neoplasms. In: Hepatology Research ... Steroidogenesis in ovarian-like mesenchymal stroma of hepatic and pancreatic mucinous cystic neoplasms. Hepatology Research. ... Steroidogenesis in ovarian-like mesenchymal stroma of hepatic and pancreatic mucinous cystic neoplasms. / Kumata, Hiroyuki; ... Mucinous cystic neoplasms are known to harbor ovarian-like mesenchymal stroma (OLS) expressing progesterone and estrogen ...
Benign, Histopathology, Malignant, Ovarian neoplasms Abstract. Background: Ovarian tumours account for one of the top five ... Study of histomorphological spectrum of ovarian neoplasms: an institutional perspective Authors. * Swarnalatha P. Department of ... Methods: The study comprises of retrospective clinico pathological evaluation of 77 cases of ovarian neoplasms in Indian Red ... Pattern of ovarian neoplasm in eastern U.P. J obstetr Gynaecol, 1990; 41(2):242-6. ...
Return to Article Details Xanthogranulomatous oophoritis-masquerading as ova-rian neoplasm: report of two cases Download ...
Prevalence of malignancy was 29% (49 primary invasive epithelial ovarian cancers, 18 borderline ovarian tumours, and 7 ... The purpose of this study is to evaluate the diagnostic performance of the International Ovarian Tumour Analysis (IOTA) ... Correct characterisation of ovarian tumours is critical to optimise patient care. ... Although ovarian tumours are common, most are not malignant (Menon et al, 2009). Correctly characterising ovarian tumours is ...
MAIN OUTCOMES AND MEASURES: Unnecessary oophorectomies, defined as oophorectomy for a benign ovarian neoplasm based on final ... interventional study of a risk stratification algorithm in patients aged 6 to 21 years undergoing surgery for an ovarian mass ... ability of a consensus-based preoperative risk stratification algorithm to discriminate between benign and malignant ovarian ... Although most ovarian masses in children and adolescents are benign, many are managed with oophorectomy, which may be ...
Ovarian Neoplasm Imaging. Springer Science & Business Media. p. 165. ISBN 9781461486336. "NCI Dictionary of Cancer Terms". ... Ovarian teratomas represent about a quarter of ovarian tumors and are typically noticed during middle age. Testicular teratomas ... Treatment of coccyx, testicular, and ovarian teratomas is generally by surgery. Testicular and immature ovarian teratomas are ... Ovarian teratomas often present with abdominal or pelvic pain, caused by torsion of the ovary or irritation of its ligaments. A ...
A case of ovarian metastasis of gall bladder carcinoma simulating primary ovarian neoplasm. 2006-01-01 Diagnostic pitfalls and ... Massive Degenerated Leiomyomas masquerading ovarian neoplasm. 2011-01-01 Pandt D Priyadarshini P Feroz MS Roopa PS Kudva R ... Abdominopelvic Tuberculosis masquerading ovarian malignancy - Histopathology key to Management. 2014-01-01 Bharthur S Ramkumar ... Sinonasal - Type Hemangiopericytoma of Nasal Cavity: A Rare Neoplasm- Case Report with a Brief Review of Literature. 2014-01-01 ...
Ovarian Neoplasms / diagnosis* * Ovarian Neoplasms / genetics * Practice Guidelines as Topic / standards* Substances * BRCA1 ...
Borderline ovarian tumors are abnormal cells or growths that develop in the ovaries. Although they are not cancerous, they may ... 2010). Current update on borderline ovarian neoplasms. https://www.ajronline.org/doi/10.2214/AJR.09.3936. ... Ovarian cancer testing: What can it involve?. Ovarian cancer treatment can be more effective if a person receives an early ... Home remedies for ovarian cyst symptoms. In this article, we look at which home remedies can help reduce ovarian cyst symptoms ...
Maximal effort cytoreductive surgery is associated with improved outcomes in advanced high-grade serous ovarian cancer (HGSOC ... A randomized trial of lymphadenectomy in patients with advanced ovarian neoplasms. N. Engl. J. Med.380, 822-832 (2019). ... 1: Complete gross tumour resection is associated with improved prognosis in advanced stage high-grade serous ovarian cancer ... Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer. N. Engl. J. Med.381, 2403-2415 (2019). ...
International Collaborative Ovarian Neoplasm trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ... ovarian cancer.. Nicoletta Colombo, David Guthrie, Stefania Chiari, Mahesh Parmar, Wendi Qian, Ann Marie Swart, Valter Torri, ... question of whether platinum-based adjuvant chemotherapy can improve outcomes in patients with early-stage epithelial ovarian ... chemotherapy would improve overall survival and prolong recurrence-free survival in women with early-stage epithelial ovarian ...
Ovarian neoplasms. Ovary. Postmenopause. Sertoli-Leydig cell tumor. Sex cord-gonadal stromal tumors. Stromal cells. Virilism. ... Virilizing ovarian tumors (VOT) and ovarian stromal hyperthecosis (OH) are the most common hyperandrogenism etiologies in the ... Moreover, imaging may not accurately characterize these ovarian lesions. Due to the difficulties in establishing the ... serum levels of testosterone and gonadotropins and presence of ovarian nodule in the pelvic MRI. Although the association of ...
Pelvic Spleen Masquerading as an Ovarian Neoplasm. A Khalid, F Lawton A 53-year-old Caucasian woman, a receptionist in a ... Bowel Surgery for Epithelial Ovarian Cancer - An Early Case Series. Y N Chia, E H Tay, D M O Cheong, K W Eu, J Low, T H Ho, K L ... Occult Virilizing Ovarian Tumours in Postmenopausal Women: Problems in Evaluation with Reference to a Case. K C Loh, J C Lo, C ... Occult Virilizing Ovarian Tumours in Postmenopausal Women: Problems in Evaluation with Reference to a Case. K C Loh, J C Lo, C ...
Pelvic Spleen Masquerading as an Ovarian Neoplasm. A Khalid, F Lawton A 53-year-old Caucasian woman, a receptionist in a ... Ovarian carcinoma is the most frequent cause of death from gynaecological malignancies in the United States. Rates for ovarian ... Occult Virilizing Ovarian Tumours in Postmenopausal Women: Problems in Evaluation with Reference to a Case. K C Loh, J C Lo, C ... Occult Virilizing Ovarian Tumours in Postmenopausal Women: Problems in Evaluation with Reference to a Case. K C Loh, J C Lo, C ...
This value can also be seen with an ovarian neoplasm, yielding false-positive results. View Media Gallery ... 36] US scan characteristics of endometriomas overlap with other pathologies, such as ovarian neoplasms. Endometriomas are ... This value can also be seen with an ovarian neoplasm, yielding false-positive results. ... Imaging evaluation of ovarian masses. Radiographics. 2000 Sep-Oct. 20(5):1445-70. [QxMD MEDLINE Link]. [Full Text]. ...
Low-grade Fibromyxoid Sarcoma Presenting Clinically as a Primary Ovarian NeoplasmWinfield HL, De Las Casas LE, Greenfield WW, ... Chapter 3 Ovarian carcinosarcomaTymon-Rosario J, Chui M, Santin A. Chapter 3 Ovarian carcinosarcoma. 2023, 41-54. DOI: 10.1016/ ... Immunological treatment of ovarian cancerCannon MJ, Santin AD, OBrien TJ. Immunological treatment of ovarian cancer. Current ... Low-grade Fibromyxoid Sarcoma Presenting Clinically as a Primary Ovarian Neoplasm. International Journal Of Gynecological ...
Benign Epithelial Neoplastic Ovarian Cysts. Epithelial cystic tumors account for about 60% of all true ovarian neoplasms. One ... When ovarian neoplasms are encountered in girls of this age group, they fall into the germ cell, epithelial cell, and stromal/ ... 5] Fibromas are the most common benign ovarian neoplasms. These tumors occur most commonly in women of postmenopausal age. They ... Ovarian Lesions Before Birth and During Childhood. Benign ovarian cysts are common and can appear at various times throughout a ...
Expression of P16 in Surface Epithelial Ovarian Neoplasm Nondita Mudi, Nazneen Nahar Ayman, Rumana Sharmin, Reba Das, ...
Ovarian Neoplasms. *Peritoneal Neoplasms. *Fallopian Tube Neoplasms. .map{width:100%;height:300px;margin-bottom:15px;} Name. ... concurrent radiotherapy for ovarian cancer Surgery: At least 2 weeks since prior. surgery,except for insertion of central ... refractory or recurrent ovarian epithelial, primary peritoneal, or fallopian tube cancer.. II. Compare the tolerability of ... DISEASE CHARACTERISTICS: Histologically or cytologically confirmed ovarian epithelial. cancer, primary peritoneal cancer, or ...
Ovarian Neoplasms. Prostatic Neoplasms Publication Types: Lecture. Webcast Download. NLM Classification: WP 322 ... TRACO: Ovarian Cancer & Prostate Cancer. Download VideoCast. You can download this VideoCast and play it on your device. There ...
Diminished ovarian reserve. *Luteal dysfunction. *Premature menopause. *Gonadal dysgenesis (Turner syndrome). *Ovarian neoplasm ... Ovarian and Uterine Cycles in the Nonpregnant Woman. An ovary about to release an egg.. Ovarian Cycle Events Uterine Cycle ... Ovarian tumors,although rare, can occur. Women with ovarian tumors may have abdominal pain and masses that can be felt in the ... The reproductive cycle can be divided into an ovarian cycle and a uterine cycle (compare ovarian histology and uterine ...
MBT present similarly to other ovarian neoplasms with abdominal pain and bulk symptoms. On imaging, these tumors demonstrate ... MBT present similarly to other ovarian neoplasms with abdominal pain and bulk symptoms. On imaging, these tumors demonstrate ... MBT present similarly to other ovarian neoplasms with abdominal pain and bulk symptoms. On imaging, these tumors demonstrate ... ELSEVIER SCIENCE INC: 26-31.,detail:{html:,h4>Abstract,/h4>\n ,p class=\abstract\>Ovarian neoplasms are a heterogeneous ...
  • Ovarian cancer is a cancerous tumor that forms in the tissues of an ovary. (medlineplus.gov)
  • Steroidogenesis in hepatic mucinous cystic neoplasm: Aim Mucinous cystic neoplasms (MCNs) occur in the ovary, pancreas, and retroperitoneum but very rarely in the liver. (elsevierpure.com)
  • H-scores of cytochrome P450 17α-hydroxylase/c17-20 lyase (P450c17) and 5α-reductase-1 (5αRED-1) in the stroma were significantly higher in OLS of hepatic and pancreatic MCN than in the stroma of ovarian MCN and normal ovary. (elsevierpure.com)
  • A struma ovarii (also known as goitre of the ovary or ovarian goiter) is a rare form of mature teratoma that contains mostly thyroid tissue. (wikipedia.org)
  • Borderline ovarian tumors (BOTs) are abnormal cells or growths that develop in the tissue encapsulating an ovary. (medicalnewstoday.com)
  • Angiosarcoma of the ovary is rare but represents an aggressive type of malignant ovarian neoplasms. (hindawi.com)
  • Most tumors are confined to the ovary at diagnosis, and malignant Brenner tumors have a better prognosis than other epithelial ovarian carcinomas. (cap.org)
  • subsequently, this group of tumors of the ovary were classified in 1973 by the World Health Organization as "low malignant potential ovarian tumor" [ 2 ] and, finally, in 2003 WHO separates them from carcinomas and call them borderline tumors. (intechopen.com)
  • This can be easily mistaken for neoplasm, in which case the appropriate treatment will be removal of the whole ovary. (who.int)
  • The study included 982 patients with benign, borderline, and malignant ovarian neoplasms and normal ovary. (biomedcentral.com)
  • Both tubal structures (hydrosalpinx, hydatids) and congenital broad ligament cystic masses (paramesonephric remnants) can appear to be ovarian cysts if the ovary is not seen in imaging separately on that side. (wdxcyber.com)
  • Neoplasms of the ovary occur infrequently but when they do, they usually are painless and are found only on routine examination. (wdxcyber.com)
  • Because ovarian neoplasms can show different pathologic features in the various areas of the neoplasm, the entire neoplasm is submitted for pathological examination which means removal of that entire ovary. (wdxcyber.com)
  • While it is possible that this represents a ovarian mass with mostly solid components, it is much more commonly a benign process involving the bowel, tube or adhesive disease around the ovary. (wdxcyber.com)
  • The question of whether platinum-based adjuvant chemotherapy can improve outcomes in patients with early-stage epithelial ovarian cancer is an important one. (nih.gov)
  • We carried out a multicenter, open randomized trial to determine whether adjuvant chemotherapy would improve overall survival and prolong recurrence-free survival in women with early-stage epithelial ovarian cancer. (nih.gov)
  • These results suggest that platinum-based adjuvant chemotherapy improves survival and delays recurrence in patients with early-stage ovarian cancer. (nih.gov)
  • Histologically confirmed International Federation of Gynecology and Obstetrics (FIGO) stage (67) III or IV ovarian epithelial cancer or primary peritoneal cancer at presentation. (bayer.com)
  • Histologic subtypes of ovarian cancer other than epithelial (i.e. sarcoma, lymphoma, germ cell). (bayer.com)
  • What is ovarian cancer? (medlineplus.gov)
  • What are the types of ovarian cancer? (medlineplus.gov)
  • There are a few different types of ovarian cancer. (medlineplus.gov)
  • These two cancers are similar to ovarian cancer, and they have the same treatments. (medlineplus.gov)
  • So some medical experts also consider those two types as ovarian cancer. (medlineplus.gov)
  • Some other rarer types of ovarian cancer are malignant germ cell tumors and stromal tumors. (medlineplus.gov)
  • Ovarian cancer happens when there are changes (mutations) in the genetic material (DNA). (medlineplus.gov)
  • Ovarian cancer that is caused by inherited genetic changes is called hereditary ovarian cancer. (medlineplus.gov)
  • There are also certain genetic changes that can raise your risk of ovarian cancer, including changes called BRCA1 and BRCA2 . (medlineplus.gov)
  • Besides genetics, your lifestyle and the environment can affect your risk of ovarian cancer. (medlineplus.gov)
  • Who is more likely to develop ovarian cancer? (medlineplus.gov)
  • Certain people are more likely to develop ovarian cancer. (medlineplus.gov)
  • What are the symptoms of ovarian cancer? (medlineplus.gov)
  • Ovarian cancer may not cause early signs or symptoms. (medlineplus.gov)
  • How is ovarian cancer diagnosed? (medlineplus.gov)
  • Often the only way to know for sure that you have ovarian cancer is by having a biopsy of the tissue. (medlineplus.gov)
  • What are the treatments for ovarian cancer? (medlineplus.gov)
  • Your provider may suggest that you have genetic testing to look for the gene changes that raise the risk for ovarian cancer. (medlineplus.gov)
  • Histological Classification of Ovarian Cancer. (ijmedicine.com)
  • Ovarian Cancer Development and Metastasis. (ijmedicine.com)
  • Epidemiology and screening of ovarian cancer. (ijmedicine.com)
  • Basic E, Kozaric H, Kozaric M, Suko A. Ovarian-cancer incidence and surgical approach to treatment at clinic for Gynecology and Obstetrics of Clinical Center of University of Sarajevo in 2009.Mater Sociomed, 2010;22:101-4. (ijmedicine.com)
  • According to the National Cancer Institute (NCI), around 75% of borderline ovarian tumors are stage 1 at the point of diagnosis, meaning tumors are confined to the ovaries or fallopian tubes. (medicalnewstoday.com)
  • Maximal effort cytoreductive surgery is associated with improved outcomes in advanced high-grade serous ovarian cancer (HGSOC). (nature.com)
  • Fig. 1: Complete gross tumour resection is associated with improved prognosis in advanced stage high-grade serous ovarian cancer patients. (nature.com)
  • British Gynaecological Cancer Society (BGCS) epithelial ovarian/fallopian tube/primary peritoneal cancer guidelines: recommendations for practice. (nature.com)
  • Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. (nature.com)
  • Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer. (nature.com)
  • Ovarian cancer is the most common gynaecological malignancy with over 5000 new cases diagnosed every year in the UK and 22 000 in the. (annals.edu.sg)
  • Dr. Santin's translational research program in ovarian cancer has been funded multiple times by federal agencies including the Department of Defense (DoD), the National Institute of Health (NIH) as well as private National and International Foundations. (yale.edu)
  • Newer markers for ovarian cancer are on the horizon. (medscape.com)
  • In women desiring future fertility who have stage IA low-risk ovarian cancer, conservative surgical therapy is appropriate, provided that close follow-up can be maintained. (medscape.com)
  • Ovarian cancer & prostate cancer / C. Annunziata, J. Gulley. (nih.gov)
  • p class=\'abstract\'>BACKGROUND: High-grade serous ovarian cancer (HGSOC) is the most common subtype of ovarian cancer and is associated with high mortality rates. (stanford.edu)
  • 225 primary ovarian cancer patients with well annotated clinical data and a complete debulking rate of 60% were compiled for a clinical cohort. (stanford.edu)
  • Patient and non-patient-associated co-factors, surgical skills, and center experience remain the main determining factors when considering the surgical outcome at primary debulking in high-grade serous ovarian cancer patients. (stanford.edu)
  • BACKGROUND: The serum marker CA 125 is still the most widely used biomarker for ovarian cancer (OC) diagnosis in gynecological and oncological setting, but its predictive role in early-stage OC is still debated. (minervamedica.it)
  • To further evaluate the safety and efficacy of KU-0059436 in an expanded cohort of BCRA-enriched population, primarily ovarian cancer patients. (astrazenecaclinicaltrials.com)
  • Scholars@Duke publication: Targeting Dormant Ovarian Cancer Cells In Vitro and in an In Vivo Mouse Model of Platinum Resistance. (duke.edu)
  • The protein kinase C inhibitor UCN-01 (7-hydroxystaurosporine) has shown higher efficacy against slow proliferating and/or quiescent ovarian cancer cells. (duke.edu)
  • In this study, tumorigenic potential was assessed using anchorage-independent growth assays and spheroid-forming capacity, which was determined with ovarian cancer cell lines as well as primary ovarian cancers. (duke.edu)
  • By live in vivo imaging, ovarian cancer xenograft tumors were reduced after primary treatment with carboplatin. (duke.edu)
  • CHICAGO -- Lymph node dissection had no impact on survival among women with completely resected ovarian cancer and clinically negative nodes, a large randomized trial showed. (medpagetoday.com)
  • Note that the results suggest that systematic lymph node evaluation of clinically negative lymph nodes in patients with advanced ovarian cancer and complete resection should be omitted. (medpagetoday.com)
  • Surgery to achieve macroscopic complete resection is the major therapeutic goal in patients with primary advanced ovarian cancer. (medpagetoday.com)
  • Eligible patients had FIGO IIB-IV ovarian cancer considered feasible for macroscopic complete resection, clinically and radiographically negative pelvic and para-aortic lymph nodes, no prior chemotherapy, and no prior lymph node dissection. (medpagetoday.com)
  • Several CTAs, including NY-ESO-1, MAGE-A3, and MAGE-A4, have been or are being studied as target antigens in vaccine clinical trials for various types of tumors, including non-small-cell lung cancer, ovarian cancer, gastrointestinal carcinoma, and urothelial carcinoma ( 7, 9 - 13 ). (aacrjournals.org)
  • For ovarian/fallopian tube cancer, the staging system developed by the International Federation of Obstetrics and Gynecology (Federation Internationale de Gynecologie et d'Obstetrique, or FIGO) is used. (cancer.net)
  • No cancer is found on the ovarian or fallopian tube surface or in the abdomen. (cancer.net)
  • Epidemiologic evidence indicates that lower circulating vitamin D levels are associated with a higher risk of ovarian cancer and that vitamin D supplementation is associated with decreased cancer mortality. (mdpi.com)
  • We conducted a systematic review of the literature on the effects of vitamin D on ovarian cancer cell. (mdpi.com)
  • BOT typically occurs in women 10 years younger than those with epithelial ovarian cancer, and the majority of the women with BOT are diagnosed in the earlier stages, with 75% diagnosed at stage I [1, 2]. (researchsquare.com)
  • Prior small studies have shown increased expression of sperm protein 17 (Sp17) in epithelial ovarian cancer (EOC) tissue and suggest Sp17 as a potential biomarker for EOC. (biomedcentral.com)
  • Epithelial ovarian cancer (EOC) is the fifth most common cause of female cancer-related deaths. (biomedcentral.com)
  • One CTA that has been proposed as a potential biomarker for ovarian cancer is sperm protein 17 (Sp17). (biomedcentral.com)
  • Surgery is the initial modality of treatment for stage I-IVA epithelial ovarian cancer. (medscape.com)
  • However, only a small percentage of women with epithelial ovarian cancer can be treated with surgery alone. (medscape.com)
  • Women with any stage of epithelial ovarian cancer should be considered for clinical trials if available. (medscape.com)
  • 1 cm) stage III ovarian cancer after front-line surgery. (medscape.com)
  • En 11 annees (1er janvier 1998-31 decembre 2008) 9946 patientes ont ete operes dans notre servie dont 29 pour le cancer de l'ovaire soit 0;29. (bvsalud.org)
  • Masses that are symptomatic or do not resolve may need to be removed surgically to be treated and checked for ovarian cancer. (msdmanuals.com)
  • Diagnosis Ovarian cancer is often fatal because it is usually advanced when diagnosed. (msdmanuals.com)
  • The most common histology-high-grade serous epithelial ovarian cancer-is considered as a single clinical entity along. (msdmanuals.com)
  • Gliomatosis peritoneii, which presents as a deposition of mature glial cells in the peritoneum, is almost exclusively seen in conjunction with cases of ovarian teratoma. (wikipedia.org)
  • Through genetic studies of exome sequence, it was found that gliomatosis is genetically identical to the parent ovarian tumor and developed from cells that disseminate from the ovarian teratoma. (wikipedia.org)
  • It has been noted that fetiform teratoma is reported more often (by gynecologists) in ovarian teratomas, and fetus in fetu is reported more often (by general surgeons) in retroperitoneal teratomas. (wikipedia.org)
  • In the remaining cases, angiosarcoma was associated with ovarian teratoma or epithelial neoplasm [ 2 , 4 ]. (hindawi.com)
  • Recurrent ovarian immature teratoma in a 12-year-old girl: Implications for management. (cam.ac.uk)
  • OBJECTIVE: To evaluate the ability of a consensus-based preoperative risk stratification algorithm to discriminate between benign and malignant ovarian pathology and decrease unnecessary oophorectomies. (childrensmercy.org)
  • At present, serum CA-125 is the most extensively used biomarker to preoperatively discriminate between benign and malignant ovarian neoplasms, detect recurrence, and monitor response to treatment. (biomedcentral.com)
  • To our knowledge, less than 40 cases of ovarian angiosarcoma have been reported in English literature [ 1 - 3 ]. (hindawi.com)
  • Comparison of Nexavar with a placebo as maintenance therapy for patients with advanced Ovarian or primary Peritoneal cancers in complete remission following surgery and one regimen of chemotherapy. (bayer.com)
  • Most ovarian cancers are caused by genetic changes that happen during your lifetime. (medlineplus.gov)
  • Prevalence of malignancy was 29% (49 primary invasive epithelial ovarian cancers, 18 borderline ovarian tumours, and 7 metastatic tumours). (nature.com)
  • Doctors also describe ovarian/fallopian tube cancers by their grade. (cancer.net)
  • They are very different from high-grade cancers and represent about 10% to 15% of epithelial ovarian/fallopian tube neoplasms, which are abnormal growths of cells. (cancer.net)
  • L'objectif de cette étude était de déterminer la fréquence des cancers gynécologiques en pratique oncologique à Lomé et d'en étudier les aspects épidémiologiques et histo-cliniques. (bvsalud.org)
  • Il s'agitd'une étude rétrospective et descriptive portant sur tous les cancers gynécologiques reçus en oncologie entre le 1erJanvier 2016 et le 31 Décembre 2021. (bvsalud.org)
  • ces cancers ont ete diagnostiques au stade avance d'ou les difficultes dans leur prise en charge chirurgicale. (bvsalud.org)
  • En consequence notre objectif a ete d'etudier la place et les caracteres de la chirurgie dans la prise en charge de ces cancers. (bvsalud.org)
  • Publications] Kobayashi M: 'Ovarian clear-cell carcinoma prodncing estradiol and human choionic bonadotrop in. (nii.ac.jp)
  • Serous cystadenoma was the commonest benign tumour and serous papillary carcinoma was the commonest malignant ovarian tumour. (ijmedicine.com)
  • He is currently funded by NIH to evaluate the potential use of Clostridium Perfringens Enterotoxin (CPE) as a novel therapy against chemotherapy resistant ovarian carcinoma. (yale.edu)
  • Most ovarian enlargement is discovered either on pelvic examination or on imaging studies such as pelvic ultrasound or CAT scans obtained for various reasons. (wdxcyber.com)
  • A pelvic the anthrax toxin is being evaluated as a choice for tumor ultrasonograph showed a left ovarian complex mass meas- cell surface targeting in chemoresistant neoplasms (5). (cdc.gov)
  • Furthermore, two of 7 postmenopausal women with epithelial ovarian tumors responded to the hCG loading test. (nii.ac.jp)
  • The steroid levels were compared with the values in postmenopausal women without ovarian tumors. (nii.ac.jp)
  • Virilizing ovarian tumors (VOT) and ovarian stromal hyperthecosis (OH) are the most common hyperandrogenism etiologies in the postmenopausal women. (usp.br)
  • Due to the difficulties in establishing the differential diagnosis between VOT and OH, bilateral oophorectomy is the treatment of choice in postmenopausal women with hyperandrogenism of ovarian origin. (usp.br)
  • A systematic review and meta-analysis by Liu et al found that the malignancy rate, including borderline tumors, for simple ovarian cysts in postmenopausal women was approximately 1 in 10,000. (medscape.com)
  • CA 125 is usually measured in postmenopausal women with an ovarian mass, but its use in premenopausal women requires clinical judgment. (msdmanuals.com)
  • The most frequently encountered neoplastic pancreatic cysts include intraductal papillary mucinous neoplasm (IPMN), serous cystadenoma (SCA), mucinous cystic neoplasm with ovarian stroma (MCN), and solid pseudopapillary epithelial neoplasm. (medscape.com)
  • Note the smooth external contour typical of a mucinous cystic neoplasm. (medscape.com)
  • Methods Both steroid receptors and steroidogenic factors were immunohistochemically evaluated using H-scores and results were compared with those in 15 ovarian MCNs and 10 normal ovaries. (elsevierpure.com)
  • Results Androgen receptor (AR) H-scores in OLS were significantly higher in hepatic, pancreatic, and ovarian MCN than those in normal ovaries. (elsevierpure.com)
  • [ 5 ] Other, rarer cystic lesions, such as solid pseudopapillary epithelial neoplasm and cystic pancreatic neuroendocrine tumor (cPNET), tend to harbor features that suggest a specific diagnosis, usually leading to surgical removal. (medscape.com)
  • Angiosarcoma may present a challenge in intraoperative frozen section diagnosis of an ovarian mass. (hindawi.com)
  • Unlike the invasive carcinomas, borderline ovarian tumors are characterized by cytoplasmic and nuclear atypia, (element of differential diagnosis with benign tumors), absence of stromal invasion, (element of differential diagnosis with malignant tumors), unusual degree of proliferation of the epithelial cells with cellular stratification including remarkable architectural atypia and the formation of papillary protuberances. (intechopen.com)
  • Mucinous cystic neoplasms are known to harbor ovarian-like mesenchymal stroma (OLS) expressing progesterone and estrogen receptors. (elsevierpure.com)
  • The ovarian stroma showed extensive oedema. (who.int)
  • A 2-year interim analysis from the International Ovarian Tumor Analysis Phase 5 (IOTA5) study showed that 80% of ovarian cysts considered benign on ultrasonography either disappeared or required no intervention. (medscape.com)
  • Benign ovarian masses include functional cysts (eg, corpus luteum cysts) and neoplasms (eg, benign teratomas). (msdmanuals.com)
  • Ovarian cysts or other ovarian masses are a common gynecologic issue. (msdmanuals.com)
  • is usually defined as a clinical syndrome, not by the presence of ovarian cysts. (msdmanuals.com)
  • Testicular and immature ovarian teratomas are also frequently treated with chemotherapy. (wikipedia.org)
  • The Chicago Consensus Working Group provides multidisciplinary recommendations for the management of ovarian neoplasms specifically related to the management of peritoneal surface malignancy. (northwestern.edu)
  • Chicago Consensus Working Group 2020, ' The Chicago Consensus on Peritoneal Surface Malignancies: Management of Ovarian Neoplasms ', Annals of surgical oncology , vol. 27, no. 6, pp. 1780-1787. (northwestern.edu)
  • Shah S, Hishikar VA. Incidence and management of ovarian tumours. (ijmedicine.com)
  • Complications may include ovarian torsion, testicular torsion, or hydrops fetalis. (wikipedia.org)
  • patients often present with ovarian torsion. (medscape.com)
  • Fig. 07 - CEUS - demonstrated the absence of vascularization of the internal echogenic mass (thus defined as a clot) and the absence of the ovarian torsion, which could occur in this case taking into consideration the voluminous cyst. (efsumb.org)
  • Her primary ted to the hospital because of a left ovarian mass torsion. (cdc.gov)
  • B. anthracis ovarian mass torsion. (cdc.gov)
  • Pancreatic cystic neoplasms represent a small yet increasingly detected entity of pancreatic abnormalities. (medscape.com)
  • Approximately 70% of pancreatic cystic neoplasms are discovered incidentally. (medscape.com)
  • Nonepithelial malignant neoplasms sometimes arise in mucinous tumors, typically as mural nodules. (hindawi.com)
  • Sp17 expression was limited in other benign and non-epithelial malignant neoplasms. (biomedcentral.com)
  • The purpose of this study is to evaluate the diagnostic performance of the International Ovarian Tumour Analysis (IOTA) logistic regression model (LR2), ultrasound Simple Rules (SR), the Risk of Malignancy Index (RMI) and subjective assessment (SA) for preoperative characterisation of adnexal masses, when ultrasonography is performed by examiners with different background training and experience. (nature.com)
  • MAIN OUTCOMES AND MEASURES: Unnecessary oophorectomies, defined as oophorectomy for a benign ovarian neoplasm based on final pathology or mass resolution. (childrensmercy.org)
  • Malignant struma ovarii is a rare ovarian neoplasm composed predominantly of mature thyroid tissue. (nel.edu)
  • Leydig cell tumors are rare ovarian steroid cell neoplasms. (scite.ai)
  • A failure to intraoperatively recognize this malignant neoplasm may result in incomplete surgical staging procedure or inappropriate clinical management. (hindawi.com)
  • This study aimed to evaluate the effect of clinicopathologic and surgical factors on the prognosis and fertility outcomes of patients with borderline ovarian tumour (BOT). (researchsquare.com)
  • Mucinous epithelial tumors account for approximately 10-15% of all epithelial ovarian neoplasms. (medscape.com)
  • Benign Brenner tumors account for approximately 5% of all benign ovarian epithelial tumors and are typically found incidentally in women in the 5th to 7th decades of life. (cap.org)
  • Non neoplastic ovarian lesions were excluded. (ijmedicine.com)
  • Thakkar N, Shah S. Histopathological Study of Ovarian Lesions. (ijmedicine.com)
  • Retrospective and prospective study of ovarian tumors and tumor-like lesions. (ijmedicine.com)
  • Moreover, imaging may not accurately characterize these ovarian lesions. (usp.br)
  • Borderline ovarian tumour (BOT) is a peculiar type of tumour with a more favourable prognosis than malignant ovarian tumours. (researchsquare.com)
  • We present the case of a 30-year-old woman with findings of massive ovarian oedema on ultrasound imaging, and a discussion and literature review aiming to clarify that this is a benign tumour-like condition which every gynaecologist can encounter and that the most appropriate treatment is conservative surgery. (who.int)
  • Ultrasound examination showed a large left ovarian hypoechoic homogenous solid mass lesion 7 × 6 cm ( Figure 1 ), which showed poor vascularity on colour Doppler scan. (who.int)
  • The hLH and hFSH binding characteristics of the ovarian tumors were similar to those of the normal ovarian tissue. (nii.ac.jp)
  • Similar to other epithelial ovarian tumors, Benner tumors are classified as benign, borderline/atypical proliferative, or malignant. (cap.org)
  • Borderline ovarian tumors represent 10-20% of epithelial ovarian neoplasm's [ 5 ] with an incidence of 1.8-4.8 out of 100.000 women per year [ 6 ] and typically have an excellent prognosis. (intechopen.com)
  • A 35 cm right ovarian mass submitted for intraoperative consultation was a multicystic mucinous tumor with an 8 cm area of hemorrhagic lesion between cystic locules. (hindawi.com)
  • A macroscopic hemorrhagic area in an ovarian mucinous tumor should be evaluated with care, and the possibility of angiosarcoma should be borne in mind. (hindawi.com)
  • Gross and microscopic histopathological examination was done for ovarian neoplasms. (ijmedicine.com)
  • Histopathological profile of ovarian tumours: A twelve year institutional experience. (ijmedicine.com)
  • Histopathological study of ovarian tumors in Ajmer region. (ijmedicine.com)
  • DESIGN, SETTING, AND PARTICIPANTS: Pre/post interventional study of a risk stratification algorithm in patients aged 6 to 21 years undergoing surgery for an ovarian mass in an inpatient setting in 11 children's hospitals in the United States between August 2018 and January 2021, with 1-year follow-up. (childrensmercy.org)
  • Treatment of coccyx, testicular, and ovarian teratomas is generally by surgery. (wikipedia.org)
  • Most ovarian teratomas are mature. (wikipedia.org)
  • Ovarian teratomas represent about a quarter of ovarian tumors and are typically noticed during middle age. (wikipedia.org)